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ABSTRACT 
 
 
 The World Health Organization acknowledges that single-use medical devices 
(SUDs) are commonly reprocessed and reused beyond their intended life to deliver 
patient care in low-resource settings. SUDs originally intended for use on one patient for 
one procedure are “reprocessed” in such cases, which involves cleaning, disinfection or 
sterilization, and functional testing before they are reused in hospitals. Studies have 
shown that reuse of SUDs in countries where reprocessing is unregulated can be safe if 
stringent standard operating procedures are followed. 
 The broad objective of this thesis was to validate a reprocessing protocol for the 
bag-valve-mask (BVM), a single-use device commonly reused in low- and middle-
income countries. This device is critical for supporting neonatal resuscitation in low- and 
middle-income countries, where neonatal mortality due to failure to establish breathing 
has a prevalence of roughly 19%. This was accomplished by documenting reprocessing 
practices in a tiered healthcare system in Tanzania and assessing cleaning markers and 
functional performance parameters for BVM exposed to a bleach-based reprocessing 
protocol under simulated worst-case conditions and by defining human factors affecting 
BVM reprocessing.  
Tanzanian hospital personnel interviews revealed variations in reprocessing 
practices and demonstrated a need for validated reprocessing protocols and screening 
methods for single-use devices. The bleach-based protocol was validated to meet 
disinfection targets established by the FDA, and its efficacy was unaffected by simulated 
worst-case conditions including high organic load, low hypochlorous acid presence (pH 
 iii 
~11), and prolonged drying of bioburden following simulated use. The BVM met 
performance targets even after multiple reprocessing cycles and simulated abrasive wear. 
Finally, the usability study defined human factors relevant to user compliance with the 
validated bleach-based protocol. This body of work ultimately provides a comprehensive 
framework for validating reprocessing protocols for single-use medical devices such as 
the BVM. The approaches outlined in this thesis support the safe reuse of medical 
devices through reprocessing validation using protocols that are suitable for clinical or 
laboratory settings.  
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CHAPTER ONE 
INTRODUCTION: MEDICAL DEVICE REPROCESSING 
1.1 GLOBAL MEDICAL DEVICE REPROCESSING 
Global Market Outlook 
 Reprocessing is a validated process for rendering a medical device fit for reuse [1] 
and is FDA-regulated in the United States [2-4]. The global market for medical device 
reprocessing was valued at $1.079 billion in 2016 and is forecasted to grow to 
approximately $2.4 billion dollars by 2022, experiencing a compound annual growth rate 
of 10.6% [5]. The global demand for reprocessing is motivated by three main factors: (1) 
reduction in healthcare expenditure, (2) increased medical waste sustainability efforts, 
and (3) economic opportunity to enter new markets [5, 6]. Reprocessed devices are 
considered substantially equivalent to the original device at roughly half the cost, saving 
US hospitals over $250 million a year through third-party reprocessing [5, 6]. The 
healthcare sector is the second largest contributor to landfill waste in the US [7]. In the 
context of reprocessed single-use medical devices (SUDs), reprocessing can reduce 
medical waste in landfills and cut down on red bag (regulated medical waste) disposal 
costs, which can be 5 to 10 times more costly than regular waste [5, 6]. Finally, the lower 
price of reprocessed devices allows entrance into new markets on a global scale [6]. This 
enables access to medical technology for healthcare systems that are unable to support 
the expense of the new, original medical device. 
 
1.2 REPROCESSING: A SYSTEMATIC APPROACH 
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Reprocessing of Reusable Medical Devices 
Reprocessing is a multi-step process that ensures that a clinically used (also 
referred to as ‘soiled’ in this document) device is appropriately cleaned, disinfected or 
sterilized, and functionally sound before its reuse. This process begins with placing the 
used device(s) into a common bin and transporting them to central sterile supply. The 
device should be inspected for visible defects or wear, and if damage is present, the 
device should be discarded. Next, the device receives cleaning. This step involves 
physically removing biological soil and possibly microorganisms (together, this is termed 
‘bioburden’). Cleaning may remove pathogenic material in the process, but the primary 
goal is to ensure that the device’s internal/external surfaces are free of biological soil so 
that the final stage of reprocessing is fully effective. In reality, both of these steps may 
happen in tandem or in cycles. Hospital central sterile supply personnel initially may 
grossly inspect the devices during manual cleaning and perform a more thorough 
inspection with magnifying glasses under bright lights once devices are put through a 
washer. This is done in between the “dirty” and “sterile” zones of the room, as devices 
are prepared for an important phase, disinfection/sterilization. Following this, the device 
is assessed for functionality. Functionality assessments can be performed through a series 
of quick tests that evaluate key device functions. After cleaning and functionality tests are 
performed, devices are arranged in trays and packaged for sterilization units (if 
applicable). Finally, disinfection or sterilization is performed to effectively kill 
microorganisms and reduce the risk of infection. 
Risk Assessment for Reprocessed Devices 
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The Spaulding Classification provides a way of categorizing reprocessed medical 
devices based on infection risk [8]. Devices are classified into one of three categories: 
non-critical, semi-critical, and critical. Non-critical devices are exposed to topical 
surfaces (unbroken skin) and, as a result, have low risk for transmission of infectious 
agents to patients. Devices in this category require low-level disinfection. Semi-critical 
devices come into contact with mucous membranes but not sterile tissue or cavities. 
Devices in this category pose a higher risk of infection (but lower than critical 
reprocessed devices) and are free of all microorganisms. However, small numbers of 
bacterial spores are permissible. The research in this thesis will focus on reprocessing of 
semi-critical devices, which require a 6-log reduction in microorganisms to satisfy high-
level disinfection requirements. Critical devices come into contact with sterile body tissue 
and cavities and are therefore at high risk of transmitting infection to the patient should 
they be contaminated with microorganisms. Devices in this category require sterilization.  
US Regulatory Guidelines 
Reprocessing practices vary within global regulatory frameworks for medical 
devices [9]. Medical device reprocessing is regulated in the United States, Europe, 
Australia and other countries to ensure substantial equivalence of the reprocessed device 
to the original unused device [1-2, 10, 11]. One of the most pertinent documents related 
to reprocessing of medical devices is the 2002 Medical Device User Fee and 
Modernization Act (MDUFMA), which requires reprocessors to submit validation proof 
demonstrating their reprocessing procedure was effective in meeting cleaning, 
disinfection/sterilization, and functionality targets for the reused device [2]. 
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Manufacturers of reusable devices are required to provide appropriate labeling and 
thorough instructions for use for reprocessing of the device [2]. The FDA has also issued 
guidance documents that address human factors considerations in the validation of 
reprocessing protocols and development of medical devices [1, 14], which is utilized in 
this body of research. 
In addition to this, there are guidance documents addressing the experimental 
design for reprocessing validation, which recommend the use of simulated worst-case use 
conditions [1, 3, 4]. Simulated worst-case use conditions involve selecting a clinically 
relevant soil and application method that results in the most challenging test environment, 
choosing at least two appropriate soil markers, selecting inoculation test sites, and 
designating samples as positive and negative controls in the test design [4]. Additionally, 
analytical methods for detecting residual bioburden require validation [1]. This research 
upholds these guidelines in the testing of a reprocessing protocol under worst-case use 
conditions.  
Reprocessing of Single-Use Devices 
There are several reprocessing guidance and regulatory documents related to 
reprocessing validation, some of which pertain specifically to reusable devices (as 
mentioned above) [1, 4] while others pertain specifically to single-use (disposable) 
devices (SUDs). The FDA defines SUDS as a device “intended for one use, or on a single 
patient during a single procedure” [2]. In some healthcare settings SUDs are reused 
beyond their intended life in order to deliver patient care [9, 12, 13]. Regulated 
reprocessing of SUDs is often performed by third-party reprocessors who are 
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independent from healthcare facilities [21-23], although this is not always the case, 
especially for low- and middle-income countries (LMIC) where in-hospital reprocessing 
of SUDs is prevalent [9, 12, 13, 15, 20]. In these low-resource settings, medical devices 
are often reprocessed at the user-facility level and not by third-party reprocessors [18, 
19].  Despite the lack of regulation, it has generally been shown that the reprocessing of 
SUDs is a safe practice if strict decontamination procedures are followed [16, 17]. In the 
low-resource setting, the unequal distribution of medical technology and resources may 
cause variations in reprocessing practices between hospitals on different levels of the 
same tiered healthcare system [9, 13]. Due to the variation in practices, it is critical to 
understand the types of devices being reprocessed. This body of research addresses this 
need through a systematic investigation of the reprocessing practices for LMIC hospitals. 
 
1.3 PURPOSE OF RESEARCH 
  The broad objective of this thesis is to validate a reprocessing protocol for SUDs 
commonly reused in LMIC. In these studies, the bag-valve-mask (BVM) was chosen as 
the primary SUD of interest. This objective will be accomplished by fulfilling four aims 
as described in the individual chapters as follows:  
Chapter 2: Document reprocessing practices in a tiered healthcare system. This will be 
accomplished through the assessment of current SUD reuse practices in urban and rural 
hospitals in Tanzania, in efforts to identify commonly reused SUDs and evaluate current 
reprocessing procedures. 
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Chapter 3: Develop quantitative cleaning validation methods for reprocessing. This will 
be accomplished by 1) completing a comprehensive design review and identifying 
challenges to reprocessing BVMs; and 2) investigating three different residual bioburden 
analysis methods for assessing the efficacy of decontaminating a disposable BVM. 
Chapter 4: Evaluate reprocessing protocols in simulated worst-case scenarios. This will 
be accomplished by investigating: 1) the impact of organic load and post-contamination 
drying time on reprocessing protocol efficacy and 2) the effects of repeated use and 
reprocessing on BVM functional performance. 
Chapter 5: Define human factors affecting BVM reprocessing. This will be accomplished 
by 1) creating a task analysis for BVM reprocessing, 2) defining key study output 
variables, and by 3) establishing a usability study procedure that assesses defined study 
outputs. 
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CHAPTER TWO 
MEDICAL DEVICE REUSE PRACTICES IN RURAL AND URBAN HOSPITALS IN 
A LOW-RESOURCE SETTING 
2.1 INTRODUCTION 
The World Health Organization, supported by clinical studies, recognizes that 
single-use medical devices (SUDs) are commonly reprocessed and reused beyond their 
intended life in order to deliver patient care [1-10]. Termed medical device 
“reprocessing”, such practices involve cleaning, disinfection or sterilization, and testing 
before making SUDs available for reuse in hospitals. In general, reprocessing in low- and 
middle-income countries (LMIC) is commonly performed at the user-facility level in a 
hospital setting, in contrast to regulated third-party reprocessors frequently used in high-
income countries [11-14]. Moreover, given the inequitable distribution of medical 
technology resources in LMIC, variations in reprocessing practices across tiered 
healthcare systems (e.g. national versus district hospitals) may exist within the same 
country [8, 14, 15]. Given this variability of reprocessing practices, it is essential to 
document the types of SUDs being reused and related reprocessing procedures utilized 
within a given hospital system.  
In general, studies have shown that reprocessing and reuse of SUDs within LMIC 
hospitals can be safe as long as stringent standard operating procedures (SOPs) are 
followed, which helps to reduce risks associated with inadequate cleaning and device 
failure [2, 8, 20]. These SOPs must include device-specific cleaning and sterilization 
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instructions, post-reprocessing inspection criteria and define a way to manage the number 
of device reuses. The purpose of this investigation was to assess current SUD reuse 
practices in urban and rural hospitals in Tanzania in efforts to identify commonly reused 
SUDs and evaluate current reprocessing procedures. 
 
2.2 MATERIALS AND METHODS 
Tanzania is classified as a low-income country (<$1005 gross national income per 
capita) with low (~3%) government expenditure on healthcare [21, 22]. Medical device 
reprocessing methods were investigated within two urban hospitals (Urban1, Urban2) and 
one rural (Rural1) hospital. Both of the urban hospitals are located in Dar es Salaam, 
Tanzania’s largest and most populated city. The Urban1 hospital (1500 bed capacity 
serving 1000-1200 inpatients weekly) is categorized as a national hospital in Tanzania’s 
tiered healthcare system. The Urban2 hospital is categorized as a specialized hospital 
(103 bed capacity). The Rural1 hospital is considered a regional referral hospital (420 bed 
capacity serving approximately 2 million), located 300 km from the closest city of 
Arusha—the only high standard hospital in the rural Manyara region.  
On-site interviews with hospital personnel in the urban and rural hospitals were 
conducted over a 14-day period in June 2017. Hospital personnel were selected for 
interviews based on the following criteria:  employed as a doctor, nurse, biomedical 
technician, or biomedical engineer; available during the on-site visits; willing and 
approved by supervisor to participate in the interview; and possessing direct knowledge 
of reprocessing procedures within their hospital. Each participant was interviewed by a 
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lead research team member using a structured questionnaire addressing the following 
topics: 
1) Are SUDs repeatedly reused in the hospital?  
2) What are the common types of SUDs currently being reused? 
3) What cleaning, decontamination, or other reprocessing procedures are used with the 
SUDs? 
4) Are inspection criteria or other validation protocols applied to the SUDs prior to reuse? 
 
2.3 RESULTS 
Urban Hospital Assessment 
Hospital personnel interviews identified SUDs commonly reused within the urban 
hospitals, including oxygen concentrator humidifier cups (Figure 2.1), oxygen tubes, bag-
valve-masks, electrosurgical pencils (Figure 2.2), and electrosurgical dispersive 
electrodes (Table 2.1). A written decontamination SOP for devices without electrical 
components was identified, which involved exposure to a diluted bleach solution, 
followed by a water rinse and air drying (Appendix C.1). The humidifier cups were not 
considered to be at high risk for contamination and were rinsed using tap water before 
reattachment to the oxygen concentrator (Figure 2.2). SUDs with electrical components 
were wiped with an alcohol wipe and did not undergo additional reprocessing. No 
inspection criteria were documented or in place for SUDs in either Urban1 or Urban2. 
Hospital personnel conveyed that the SUDs underwent reprocessing and reuse until the 
device malfunctioned. Therefore, the decision tree for reusing SUDs in the urban 
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hospitals involved two key decision points: observed device malfunction during prior use 
and identification of any SUD electrical components (Figure 2.3). 
  
Figure 2.1. Identified Reused SUDs. Left: Oxygen concentrator and humidifier 
attachment (non-functional). Right: (A) Electrosurgical pencil, (B) connector, (C) 
Electrosurgical pencil and connector. 
 
Table 2.1. Urban Hospital Reuse Practices. This provides a summary of reused SUDs 
in Urban1 and Urban2 hospitals, availability of decontamination SOP, and application of 
inspection criteria prior to reuse. 
Single-Use Device Reused? SOP? 
Inspection 
Criteria? 
Humidifier Cup √ √  
Oxygen Tubes √ √  
Bag-Valve-Mask √ √  
Electrosurgical Dispersive 
Electrode 
√   
Electrosurgical Pencil √   
A C 
B 
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Figure 2.2. Urban Hospital Humidifier Attachment Reuse. This reuse cycle pertains 
to the oxygen concentrator humidifier cup attachments when not following the urban 
hospital decontamination SOP. 
 
 
Figure 2.3. Urban Hospital SUD Reuse. This reuse cycle is relevant to Urban1 and 
Urban2.   
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Rural Hospital Assessment 
Hospital personnel interviews identified several commonly reused SUDs in the 
rural hospital, including oxygen concentrator humidifier cups and disposable surgical 
gowns (Table 2.2).  Additionally, it was reported that electrosurgical pencils and 
dispersal electrodes were not reused due to lack of device availability and lack of 
confidence in the hospital staff’s ability to clean the device. Rural1 did not have a written 
decontamination SOP for SUDs; instead, SUDs were cleaned in a detergent solution 
without additional cleaning or sterilization procedures. Similar to practices in the urban 
hospitals, humidifier cups were rinsed with water before reuse. Rural1 did not document 
formal inspection criteria; SUDs were disposed if there were visible defects or if cleaning 
was impeded but were otherwise reprocessed and reused until the device malfunctioned. 
Aside from looking for obvious physical defects, the decision tree for reusing SUDs in 
Rural1 involved one key decision point: identification of any electrical components for 
the SUD (Figure 2.4). 
Table 2.2. Rural Hospital Reuse Practices. This provides a summary of reused SUDs in 
Rural1 hospital, availability of decontamination SOP, and application of inspection 
criteria prior to reuse. 
Single-Use Device Reused? SOP? 
Inspection 
Criteria? 
Humidifier Cup √   
Surgical Gown √   
Electrosurgical 
Dispersive Electrode 
   
Electrosurgical Pencil    
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Figure 2.4. Rural Hospital SUD Reuse. Current SUD reuse practices within a rural 
Tanzanian hospital (Rural1). 
 
2.4 DISCUSSION 
This study identifies key risks in reprocessing procedures and provides useful 
information to aid quality improvement in SUD reprocessing. The information provided 
through the on-site interviews highlights key findings related to selection of cleaning 
solutions for reprocessing and sorting devices based on both risks of infection and device 
malfunction. In many cases, SUDs were continually reused until malfunctions occurred. 
In all interviewed hospitals, there was an absence of documented and verified standard 
operating procedures for cleaning, disinfection, and inspection, which are key aspects of 
regulated reprocessing. There was widespread use of bleach due to having the following 
properties: low cost, quick-acting microbicidal activity, and the ability to target a broad 
spectrum of microorganisms. However, it was recognized that bleach would not be 
compatible with devices containing electrical components, which led to the use of alcohol 
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wipes as the primary disinfectant for such devices. Alcohol wipes can provide rapid 
viricidal and bactericidal activity when used at appropriate concentrations (e.g. 60-80%) 
but notably lack sporicidal action and the ability to penetrate surface-adhered bioburden 
necessary for sterilizing medical devices [24]. It was noted that hospital personnel 
expressed lack of confidence in cleaning effectiveness for some devices, which could be 
addressed through well-designed validation studies. Additionally, validating device-
specific SOPs for reused SUDs and defining the number of safe reuse cycles, which is 
recommended by international regulatory standards and medical professionals, can help 
ensure safe reuse of these devices [12-17, 23, 24, 27]. 
 
2.5 CONCLUSION 
This investigation revealed a clear need to document reprocessing methods and 
SUDs commonly reused in LMIC hospitals. A broad range of reprocessed SUDs were 
identified in the included Tanzanian hospitals. Both urban and rural hospitals identified 
similar types of SUDs for reuse (Tables 2.1-2.2) but, reported varied reprocessing 
procedures. This systematic documentation of unregulated reprocessing practices (Table 
2.3) is a first step towards determining policies for safely reusing medical devices in 
hospitals throughout Tanzania and training biomedical technicians/engineers to provide 
support for such practices. While these hospital interviews provided valuable insight into 
reprocessing practices and the reuse of SUDs, it remains to be determined if the SUDs 
and reprocessing practices documented in this study are common across the broader 
hospital system in Tanzania. Collaboration with academic institutions in the country is 
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key to in-depth and formal documentation of reuse practices between hospital tiers within 
Tanzania. Moving forward, next steps include formally documenting reuse practices at 
different Tanzanian hospitals through collaboration with Tanzanian universities. 
Additionally, ongoing efforts include the validation of identified reprocessing protocols 
under realistic, worst-case conditions through microbiological testing and human factors 
studies. 
 
Table 2.3. Tanzanian Hospital Reuse Practices Summary. This provides a comparison 
of reuse-practices between urban and rural hospitals in Tanzania. 
Single-Use 
Device 
Hospital Reused? SOP? 
Inspection 
Criteria? 
No Electrical 
Components 
Urban √ √  
Rural √   
Has Electrical 
Components 
Urban √   
Rural    
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CHAPTER THREE 
REPROCESSING PROTOCOL EFFICACY AND RESIDUAL BIOBURDEN 
ANALYSES 
3.1 INTRODUCTION 
 Regulatory agencies define a single-use device (SUD) as a medical device that is 
designated by the manufacturer for use during a single medical procedure on a single 
patient and is intended to be discarded after the procedure [1-4]. However, used SUDs are 
not discarded in all circumstances; rather, they are sometimes reprocessed for reuse using 
specific methods for cleaning and disinfection. Recent trends indicate that regulated 
reprocessing is often performed by third-party reprocessors who are independent from 
healthcare facilities [4-8]. However, in-hospital reprocessing has been reported for many 
different types of SUDs and remains prevalent in many low- and middle-income 
countries (LMIC) [9-13]. 
 The current investigation was motivated by a recent survey of in-hospital 
reprocessing in Tanzanian hospitals that identified bag-valve masks (BVM) as a 
commonly reused SUD [10]. BVM are medical devices commonly used in intensive care 
units and other key hospital departments to treat patients requiring ventilation during 
manual resuscitation [14, 15]. BVM are considered an essential piece of equipment for 
newborn resuscitation [16-18]. Failure to establish breathing accounts for 19% of 
neonatal deaths, while only 3% - 6% of babies born require basic resuscitation using a 
BVM [19-21]. In LMIC with a high burden of neonatal mortality, inadequate supplies 
and poorly functioning BVM can contribute to inconsistent resuscitation practices [16]. 
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Therefore, well-executed in-hospital reprocessing could support neonatal resuscitation 
strategies by helping to maintain adequate supplies of BVM. 
 Recognized challenges with in-hospital reprocessing include variations in 
reprocessing practices between hospitals and a need for device-specific protocols 
defining reprocessing procedures and inspection criteria [8, 10, 12, 13, 22, 23]. In the 
Tanzanian survey [10], hospital personnel reported that BVM were reprocessed using a 
generalized decontamination protocol consisting of extended exposure to a dilute bleach 
solution followed by a water rinse and air-drying (Appendix C.1). However, varied 
reprocessing methods applied to some SUDs were noted, including use of alcohol wipes 
and simple water rinsing when devices were perceived as low-risk of contamination [10]. 
At present, there are limited data available for reprocessing disposable BVM. 
Manufacturers of reusable BVM propose some methods for decontamination in their 
instructions for use, but validation data are not provided [24, 25]. Those methods 
recommend the use of detergents and manual scrubbing for cleaning, the use of 
glutaraldehyde or sodium hypochlorite solutions for chemical disinfection, and the use of 
ethylene oxide or steam autoclaving for sterilization. 
 The purposes of the current study were: 1) to complete a comprehensive design 
review and identify challenges to reprocessing BVMs; and 2) to investigate three 
different residual bioburden analysis methods for assessing the efficacy of 
decontaminating a disposable BVM. 
 
3.2 MATERIALS AND METHODS 
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Design Review 
 BVM designs have basic common features, including a soft polymer mask to 
conform to the patient’s face, a deformable ventilation bag, a non-rebreathing valve 
connecting the mask to one end of the bag, and an air intake valve at the opposite end of 
the bag. Worldwide, self-inflating BVM are the most common manual ventilation device 
used in neonatal and adult intensive care units [15, 18, 26]. As described by Davies, et al. 
[15], self-inflating BVM are portable and versatile due to their ability to fill with ambient 
room air or with gas supplied from an external oxygen tank. When the ventilation bag on 
a self-inflating BVM is compressed, the non-rebreathing valve directs gas from the bag to 
the patient. As pressure on the bag is released, the non-rebreathing valve closes, and gas 
exhaled by the patient is directed out of the mask through a separate channel in the non-
rebreathing valve while the bag automatically re-inflates through the air intake valve. 
BVM can either be reusable or disposable. For the purposes of the current study, 
disposable BVM, hereafter referred to as Test BVM (Figure 3.1), were purchased from a 
commercial source (Model Life-100, Life Corporation, Milwaukee, WI). According to 
specifications provided by the manufacturer, the Test BVM consisted of a clear face 
mask fabricated from a thermoplastic polymer (polyvinyl chloride) with a removable 
rigid plastic one-way valve housing a hydrophobic filter (Filtrete™, 3M Corporation, St. 
Paul, MN). This mask features a 15-mm diameter air intake opening and a hydrophobic 
filter above the valve to protect BVM components from body fluids. 
 Several design features of the Test BVM were considered reprocessing 
challenges, including small crevices near the valve attachment, contours on the outside 
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surface, and tight folds inside the mask (Figure 3.1). These features are opportunistic 
areas for bacteria, microbes,  and physical debris buildup. The mask is made of a pliable 
material, which can add to the challenge of reprocessing [27]. Considering regulatory 
demands for worst-case contamination conditions [1], the entire inside of the mask, 
including the tight folds and crevices were identified as probable worst-case locations 
where organic material would likely be present and could become entrapped. For this 
reason, residual bioburden measurements were sampled from the entire inside of the 
mask, including the tight folds and crevices. For testing, a total of five Test BVM were 
purchased. Each mask was cut into two equal halves (Figure 3.1), thus producing two 
samples for analysis. The total inside surface area of each mask half was measured from a 
digital laser scan and measured 93.04 cm2. Each of the five decontamination protocols 
were repeated on two mask halves (n=2). 
 
 
 
 
 
 
Figure 3.1. Test BVM Mask. This device consisted of a pliable facemask and a rigid 
non-rebreathing valve. All residual bioburden analysis methods were completed on 
masks that were cut in half after removal of the valve. 
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Sample Preparation and Contaminants 
 The BVM is considered an oronasal mask typically covering a patient’s mouth 
and nose [28] and consequently, it may contact saliva, mucus, and microbial flora found 
in the upper respiratory tract. Many different bacteria can colonize the upper respiratory 
tract. Staphylococcus epidermidis is among the most common bacterial species to be 
found in the nasal and paranasal sinuses [29]. This gram-positive bacterial species was 
used in the current study to contaminate the Test BVM, as it is prevalent on human skin 
and most surfaces and forms a biofilm. This makes S. epidermidis a likely microorganism 
contaminating the BVM during use [30] and suitable for use in the current study. 
 Worst-case contamination conditions were achieved by fully submerging the Test 
BVM mask halves into a soil solution consisting of standard mucus test soil simulating 
mucus exposure from a cystic fibrosis patient [31] combined with Staphylococcus 
epidermidis ATCC 12228 (American Type Culture Collection, Manassas, VA). A 2% 
transfer of S. epidermidis ATCC 12228 stock culture to sterile Tryptic Soy Broth was 
prepared (1:49 dilution of culture to media) to obtain a 100 mL solution (Appendix B.1). 
The culture and media were then incubated overnight at 37˚C. The simulated mucus soil, 
termed Artificial Mucus Soil (Appendix B.1), was prepared according to an international 
standard for validation of cleaning methods for reusable medical devices [31]. The 
components of the Artificial Mucus Soil (mucin from pig mucosa, casein hydrolysate, 
sodium chloride, diethylene triaminepentaacetic acid, ASTM Water Type I, potassium 
chloride, salmon sperm DNA, freeze dried egg yolk emulsion, and phosphate buffered 
saline) were mixed on a stir plate at 20˚C - 25˚C to produce a uniform solution. This 
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artificial soil provided protein, total organic carbon, nucleic acids, and carbohydrates as 
cleaning markers for the residual analyses. The overnight S. epidermidis cultures were 
added to Artificial Mucus Soil at a concentration of 10% inoculum, which provided the 
addition of bacteria as a cleaning marker for the residual analysis. The Test BVM were 
fully immersed in the Artificial Mucus Soil containing the S. epidermidis. This mixture 
was incubated for 24 hours at 37˚C and, set out to dry for 15 minutes before undergoing 
one of five reprocessing protocols. Inoculum concentrations for the decontamination 
studies can be found in Appendix A.1. 
Decontamination Protocols 
 Decontamination requires cleaning of the device to the point where visible 
bioburden is removed. According to FDA regulatory classifications, BVM are semi-
critical reprocessed devices due to contact with mucous membranes (but not sterile 
tissue); therefore, the decontamination protocols for cleaning must remove visible 
bioburden and achieve high-level disinfection to eliminate microorganisms [1]. High 
level disinfection intends to kill vegetative bacteria, but it does not eliminate all spores 
[32]. High-level disinfection requires a 6-fold reduction of colony forming units (CFU), 
plus overkill as a measure of microorganisms in residual bioburden. A high log reduction 
value corresponds to an overall high bioburden removal as a result of cleaning and 
disinfection. This 6-fold reduction in CFU was the targeted goal for the experimental 
decontamination protocols in the current study. 
 Five decontamination protocols, including three experimental protocols and 
positive and negative controls, were applied to the Test BVM masks following 
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contamination. The negative control was designed to yield a high bioburden and included 
masks that did not undergo any decontamination (Figure 3.2). The positive control was 
designed to eliminate all bioburden. The positive control consisted of submerging the 
BVM in full strength (5.25%) sodium hypochlorite solution (Clorox bleach, The Clorox 
Company, Oakland, CA), then hot (>40˚C) water with non-enzymatic detergent (Versa-
CleanTM Multi-Purpose Cleaner, Thermo Fisher Scientific, Waltham, MA), and lastly in 
filtered deionized water  (ASTM type I) (Figure 3.3). For each protocol step, the mask 
was sealed in a container with the appropriate decontamination agents for that step and 
placed on a vortex mixer for one minute. Following this, the same mask and container 
were sonicated for 10 minutes before moving to the next decontamination agent. 
 The three experimental decontamination protocols were chosen based on hospital 
reprocessing observations at three hospitals in Tanzania [10]. The Alcohol Wipe protocol 
involved wiping the entire in-side of the mask with one 70% isopropyl alcohol wipe 
(Medium Sterile Alcohol Prep Pads (2.7 × 6.6 cm), Fisher HealthCare, China) (Figure 
3.4). The Water Rinse protocol involved submerging the entire mask half in ASTM Type 
I water for 10 minutes (Figure 3.5). The Soap and Bleach protocol involved sequential 
10-minute submersion of the mask half in a 0.5% sodium hypochlorite solution, a non-
enzymatic detergent (1:10 dish soap to water), and ASTM Type I water (Figure 3.6). 
Following decontamination, each mask was air-dried for 10 minutes before being 
evaluated for residual bioburden. 
 
 29 
 
 
 
 
 
Figure 3.2. Negative Control Protocol. 
 
Figure 3.3. Positive Control Protocol. 
 
 
 
 
 
 
 
Figure 3.4. Alcohol Wipe Protocol. 
 
Figure 3.5. Water Rinse Protocol. 
 
 
Figure 3.6. General Disinfection Protocol (soap and bleach). This soap and bleach 
protocol is currently in use at an urban Tanzanian hospital [10]. 
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Residual Bioburden Analytical Methods 
 Three analytical methods were selected to evaluate the residual bioburden on the 
Test BVM following each decontamination protocol (Table 3.1). Sample collection for 
Metrics 1 and 3 involved swabbing the total inside surface area of each half BVM 
immediately after cleaning, except for the negative control cases that were swabbed 24 
hours after contamination. Sample collection for Metric 2 involved swabbing 
approximately one-fourth of the inside surface area due to the manufacturer’s 
recommendation to use a small sampling area. 
Table 3.1. Residual Bioburden Analyses. 
Metric 
Residual 
Bioburden 
Method 
Tests For Units Target 
Metric 1 1ChannelCheck™ 
Protein, 
Carbohydrates, 
Hemoglobin 
N/A 
No Color 
Change 
Metric 2 
2Ruhof ATP 
Complete® 
Presence of ATP RLU < 100 
Metric 3 
Standard Plate 
Count 
Removal of Bacteria 
Log 
Reduction of 
Bacteria 
≥ 6-log 
reduction 
1Healthmark Industries Company, Inc, Fraser, MI 
2Ruhof Corporation, Mineola, NY. 
 Metric 1 was a commercial method that provided a quick (~2 minutes), qualitative 
assessment of cleanliness by detecting the presence of residual carbohydrates, protein, 
and hemoglobin on sample swabs. Test strips provided by the manufacturer featured 
three colored pads that indicated the presence of physical bioburden in the swabbed 
region. According to the manufacturer, the detection limits for the test strips are ≥210 
µg/mL for carbohydrate, ≥120 µg/mL for protein, and ≥0.25 µg/mL for hemoglobin. For 
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this study, decontamination targets were met, when both trials showed no indicator color 
change on any test strip pad. This was consistent with reduction of residual 
carbohydrates, protein, and hemoglobin below detection limits during decontamination. 
 Metric 2 (Appendix B.3) was a commercial method that provided a quick (~10 
seconds), quantitative assessment of cleanliness by detecting the presence of residual 
ATP on sample swabs. Reagent vials provided by the manufacturer emit 
bioluminescence, which correlates to certain ATP levels and was detectable as light 
emission when inserted into a handheld device also provided by the manufacturer. 
According to the manufacturer, the detection limit is 0.2 mg protein per swab, and a 
surface can be considered “clean” if the RLU (relative luminescence units) value 
displayed is less than 100. For this study, decontamination targets were met when both 
trials had RLU less than 100. 
 Metric 3 (Appendix B.2) was a commonly utilized microbiological technique 
(standard plate count) that provided a quantitative assessment of disinfection by detecting 
the presence of residual bacteria on sample swabs, which present as CFUs on agar plates. 
Plate counts of CFUs were repeated in triplicate for swabs from each Test BVM half 
mask, averaged, and then divided by the plate dilution to obtain the concentration of 
bacteria in the original sample. Overall log reduction of CFUs for a given 
decontamination protocol was calculated as the difference in bacterial concentration 
following the decontamination protocol (CP) relative to the negative control sample (CNC) 
(Equation (2.1)). 
log reduction in bacteria = log(𝐶𝑁𝐶) − log (𝐶𝑃)   (Equation 2.1) 
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 Sample collection involved swabbing the designated inside surface area of each 
half mask. Following instructions for use for Metric 1, swabs were placed into sterile test 
tubes with 10 mL of sterile Millipore (ASTM Type I) water and vortexed for one minute, 
followed by full immersion of the provided test strips into the solution and manual 
agitation for 10 seconds. The test strips were removed and held horizontally for 90 
seconds prior to reading results. The test strips were compared to the color chart provided 
by the manufacturer, and the presence or absence of residue was recorded. Following 
instructions for use for Metric 2, swabs were placed in provided reagent vials and gently 
shaken for 3 seconds prior to inserting individual vials into the hand-held unit by the 
manufacturer and recording the displayed RLU value. Following standard 
microbiological methods for Metric 3, swabs were placed into sterile test tubes with 10 
mL of sterile Millipore (ASTM Type I) water and vortexed for one minute. A ten-fold 
dilution series was prepared, plated onto agar (Tryptic Soy Agar, Remel, Lenexa, KS), 
and incubated for 24 hours at 37˚C. Results were determined by manually counting CFUs 
for each plate. 
 
3.3 RESULTS 
Design Review and Impact on Decontamination 
 Careful review of the Test BVM identified several design features that were 
considered reprocessing challenges (Figure 3.1). The mask included contours on the 
outside surface, flaps of pliable materials, tight folds, and rounded cavities on the interior 
surface. These mask features could become exposed to mucous and other biological 
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contaminants from the patient while wearing the mask, or during handling. The non-
rebreathing valve had a complex geometry, with crevices and other small design features, 
dead-end chambers, and an in-line filter. If the valve remained assembled with the mask, 
the valve-mask interface would present an additional challenge in the form of a 
circumferential small crevice between the two parts. Upon disassembly from the mask, 
the tight fit of the modular connection may be difficult to reassemble and could be a site 
for potential failure after multiple reprocessing trials. 
 As anticipated from the design review, the BVM mask design features negatively 
impacted the performance of the decontamination protocols. Based on visual examination 
of the half masks, tight folds and rounded cavities on the interior surface of the mask 
retained more water and bioburden than other areas of the mask. This was most prevalent 
after the mask was removed from the soil solution and allowed to dry, when noted mask 
regions contained pools of the soil solution. Such areas were more difficult to reach 
during manual cleaning with the alcohol wipes compared to protocols based on mask 
submersion in cleaning solutions. This was reflected in the inconsistent results for the 
Alcohol Wipe protocol (Figure 3.4) using Metric 1 and the large inter-trial differences in 
the quantitative cleanliness values for Metric 2 and Metric 3 during the Alcohol Wipe 
protocol (Tables 3.2-3.4). For example, the Alcohol Wipe protocol reached 8log10 CFU 
reduction for trial 1, consistent with a high-level disinfection benchmark, but only 
reached 3log10 CFU reduction for trial 2. One possible reason for the inconsistency was 
inadequate wiping of the inner folds of the BVM mask during the second trial. 
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Table 3.2. Metric 1 Results. 
Protocol 
Metric 1 
Target met? 
Trial 1 Trial 2 
 Protein Carb1 Hb2 Protein Carb1 Hb2  
Negative 
Control 
Yes Yes No Yes Yes No No 
Water 
Rinse 
No Yes No Yes Yes No No 
Alcohol 
Wipe 
No No No No Yes No No 
Soap and 
Bleach 
No No No Yes Yes No No 
Positive 
Control 
No No No No No No Yes 
1 Carbohydrates 
2 Hemoglobin 
 
Table 3.3. Metric 2 Results. 
Protocol 
Metric 2 
Target met? 
ATP Value (RLU) 
 Trial 1 Trial 2  
Negative Control 9999 3967 No 
Water Rinse 9999 7112 No 
Alcohol Wipe 2343 8948 No 
Soap and Bleach 0 6 Yes 
Positive Control 0 0 Yes 
 
Table 3.4. Metric 3 results. 
Protocol 
Metric 2 
Target met? 
Log Reduction in Bacteria 
 Trial 1 Trial 2  
Negative Control 0 0 No 
Water Rinse 3.7 2.5 No 
Alcohol Wipe 8.3 3.3 No 
Soap and Bleach 8.3 7.2 Yes 
Positive Control 8.3 7.2 Yes 
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Residual Bioburden Analysis 
 All three methods for assessing residual bioburden required training of personnel 
based on instructions for use (Metrics 1 and Metrics 2) or standard microbiological 
techniques (Metric 3). Metric 1 required little training outside of the swabbing technique. 
However, Metric 1 was a qualitative assessment judged by the user performing the test 
and results were highly subjective due to differences in individual ability to identify a 
change in color. Metric 2 required ample training time for: 1) proper swabbing technique; 
2) preparing the swab and reagent vial for insertion into the handheld device; and 3) 
operating the device. Metric 3 required time-intensive training for: 1) cell culturing 
techniques and use of lab equipment; 2) growing stock inoculum and culturing of 
bacteria; 3) proper inoculation of the BVM masks; and 4) growing bacterial samples on 
agar plates. 
 Based on these preliminary data, the Alcohol Wipe and Water Rinse protocols 
(Figure 3.4 and Figure 3.5, respectively) were ineffective or inconsistent at meeting 
decontamination targets. Overall, only the positive control protocol (Figure 3.3) met the 
decontamination targets for Metric 1 (Table 2.1) and only the Soap and Bleach (Figure 
3.6) and positive control protocols met the decontamination targets for Metric 2 and 
Metric 3 (Table 3.3 and Table 3.4). Full standard plate count data can be found in 
Appendices A.2 and A.3. The qualitative analysis used for Metric 1 had inter-trial 
variation, with indicators meeting cleanliness benchmarks (no color change) in trial 1 but 
not trial 2 for both the Alcohol Wipe and Soap and Bleach protocols. A color change was 
noticed for the hemoglobin indicator in the positive control protocol, but this was 
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considered a false positive because of bleach present. The quantitative analysis used for 
Metric 2 and Metric 3 had large inter-trial differences for the Alcohol Wipe protocol, as 
mentioned above, but little inter-trial variations for the other protocols. For example, the 
RLU values for Metric 2 varied within the 0 - 100 RLU benchmark (e.g. 6 RLUs in Trial 
2 for the Soap and Bleach protocol), but this is consistent with the sensitivity range of the 
system. 
 All three methods for assessing residual bioburden required some use of 
consumable materials and/or durable equipment. Metric 1 required use of consumable 
materials (swabs, test strips) to provide a qualitative assessment of residual bioburden 
(proteins, carbohydrates, hemoglobin) based on color change. Metric 2 required use of 
consumable materials (swabs, reagent vials) and durable equipment (refrigerator for 
reagent vials, hand-held device for measuring the RLU of emitted bioluminescence) to 
provide a quantitative assessment of residual ATP. Metric 3 required use of consumable 
materials (swabs, bacteria and growth media, agar plates, cell spreaders, pipette tips) and 
durable equipment (incubator, pipettes, biological hood) for measuring bacterial CFUs to 
provide a quantitative assessment of residual bacterial concentration. 
 
3.4 DISCUSSION 
 This study completed a comprehensive design review of a disposable BVM to 
identify potential challenges to reprocessing and investigated three different methods for 
assessing residual bioburden on the BVM masks following decontamination. Overall, 
only the positive control protocol (Figure 3.3) met the decontamination targets for Metric 
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1 and only the Soap and Bleach (Figure 3.6) and positive control protocols met the 
decontamination targets for Metric 2 and Metric 3. The Alcohol Wipe and Water Rinse 
protocols (Figure 3.4 and Figure 3.5, respectively) were ineffective or inconsistent at 
meeting decontamination targets (Tables 3.2-3.4). These findings provide a first step 
toward development of device-specific protocols that define uniform reprocessing 
procedures and inspection criteria for hospitals choosing to reprocess BVM. Based on a 
small sample size, these preliminary results support the use of bleach-based 
decontamination protocols that submerge disposable BVMs into cleaning and 
disinfection solutions rather than wiping. 
 The BVM mask geometry negatively impacted the performance of the 
decontamination protocols. Flaps of pliable materials, tight folds and rounded cavities on 
the interior surface of the mask were challenging to clean and contributed to large 
variations in cleanliness for Metric 2 and Metric 3 in the Alcohol Wipe protocol. 
Although only the BVM mask was evaluated in the decontamination protocols, the 
design review identified additional challenges associated with the modular connection of 
the non-rebreathing valve, as well as the complex valve geometry having small crevices, 
dead-end chambers, and a filter. All three methods required some level of training based 
on instructions for use (Metric 1 and Metric 2) or standard microbiological techniques 
(Metric 3). Metric 1 seemingly required the least training but generated the least 
consistent results. The time required for assessment after sample collection ranged from 
approximately 1-3 minutes for Metric 1 and Metric 2 and approximately one day for 
Metric 3. 
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 Several drawbacks were noted for each of the residual bioburden assessment 
methods. Metric 1 required subjective interpretation of color change and was 
incompatible with protocols involving bleach, which induced a color change falsely 
indicating the presence of hemoglobin. This inaccuracy would be problematic if 
hemoglobin was a routine contaminant for a given SUD. Possibilities for overcoming 
color interpretation include use of a colorimeter to compare the test strip to the color 
standard or taking pictures of the test strips in a uniform, well-lit environment and 
completing hue analysis. Drawbacks for Method 2 and Method 3 center on the need for 
consumables and durable equipment and extended training time, as mentioned in the 
results. 
 Several study limitations are noted. These results may not be generalizable, as 
only one model of disposable BVM was evaluated in this study. This underscores the 
need for device-specific validation of reprocessing protocols, as design features vary 
between BVM and can impact the effectiveness of decontamination protocols. While the 
design review involved the entire Test BVM (full mask and non-rebreathing valve), the 
analytical methods for residual bioburden analysis (Metrics 1-3) were evaluated using 
mask halves (n=2). This approach provided for efficient screening of the analytical 
methods, but it is recognized that additional evaluation of the full BVM (mask and valve) 
and statistical comparisons are needed for definitive conclusions related to the 
decontamination protocols. Finally, all analyses were performed by a team of five trained 
bioengineering graduate students with faculty supervision, which does not represent the 
personnel likely to conduct decontamination of disposable BVM in a healthcare setting. 
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3.5 CONCLUSION 
 This study describes an initial experimental approach for validating BVM 
decontamination protocols and generating data for objective assessment of reprocessing 
and reuse practices. The data support positive decontamination outcomes using the 
bleach-based in-hospital reprocessing protocol currently in use in some Tanzanian 
hospitals [10]. However, design features of the Test BVM mask presented clear 
challenges to cleaning and drying during the different decontamination protocols. Based 
on these preliminary results, continued assessment of the Soap and Bleach 
decontamination protocol (Figure 3.6) using complete dis- posable BVMs (full mask and 
the non-rebreathing valve connected to the mask) exposed to simulated use is warranted. 
Detailed inspection criteria, factors related to mask/valve assembly and disassembly, and 
the maximum number of intended reprocessing cycles, remain to be determined. Given 
proper consideration of training time and available resources, well-executed in-hospital 
reprocessing could support neonatal resuscitation strategies and other demands for 
manual resuscitation by helping to maintain adequate supplies of BVM. 
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CHAPTER FOUR 
REPROCESSING VALIDATION FOR THE BAG-VALVE-MASK IN SIMULATED 
WORST-CASE USE CONDITIONS 
4.1 INTRODUCTION 
 Single-use medical devices such as the disposable bag-valve-mask (BVM) 
are commonly reprocessed in hospitals in low- and middle-income countries due to 
resource constraints [1-3]. BVM are a critical medical device for neonatal resuscitation 
and the prevention of neonatal mortality associated with lack of breathing, which has a 
prevalence of roughly 19% in low- and middle-income countries [4-6]. Establishing 
rigorous reprocessing procedures for this device can enable safe reuse in low-resource 
healthcare settings. 
In a recent study evaluating different methods for quantifying decontamination of 
a disposable BVM , a simple sodium hypochlorite and detergent solution was proven 
effective for reducing bioburden and bacterial contamination under optimal cleaning 
conditions, but various BVM design features negatively impacted decontamination 
efficacy for some protocols [8]. However, only the soil application method could be 
considered a possible worst-case scenario in that study. The current study expands on 
simulated worst-case use and reprocessing scenarios. 
Sodium hypochlorite provides for high-level disinfection when appropriate 
concentrations (0.5%, 5,000 ppm chlorine) and contact time are implemented in a general 
disinfection protocol (referred to as ‘Reprocessing Protocol’ in this paper). Despite its 
lack of compatibility with some materials, this chemical is an optimal disinfectant in the 
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healthcare setting due to its quick-acting bactericidal activity, ability to deactivate a wide 
range of microbes, high water solubility, and affordability [9]. Hypochlorous acid 
provides the primary microbicidal activity of sodium hypochlorite through mechanisms 
likely related to disruption of the cell membrane and DNA synthesis [10, 11]. When 
considering factors contributing to worst-case disinfection with sodium hypochlorite, it is 
critical to consider changes in pH, chlorine concentration, and disinfectant contact time 
during reprocessing. Hypochlorous acid concentration heavily depends on the pH of the 
solution: as pH of the diluted solution increases, the microbicidal activity through the 
hypochlorous acid decreases exponentially [11]. Optimal microbicidal activity for this 
diluted solution can be found at a pH of approximately 6 [9]. Since diluted sodium 
hypochlorite solutions have a high pH, there are higher concentrations of the OCl- ion. 
This means that having the proper contact time to achieve disinfection is crucial [10, 11]. 
However, under less than ideal conditions, the sodium hypochlorite efficacy can become 
compromised. 
Several variables can impact the disinfectant quality, including the cleaning agent 
and disinfectant properties, presence of contaminants, UV exposure, and water quality [9, 
10, 12-14]. Accumulation of organic matter (biofilms and other bioburden) through 
repeated reprocessing cycles negatively impacts the microbicidal performance of sodium 
hypochlorite disinfection solution, [9, 34, 35]. Additionally, prompt cleaning of used 
devices is important to avoid drying of attached bioburden [15-17]. Prion tissue 
adsorption on stainless steel [30, 32, 33, 42] and challenges removing dried bioburden 
with a water flush through endoscope channels [31] have proven problematic. These 
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studies have shown negative effects of prolonged post-contamination drying time (i.e. the 
time between device use and the initiation of its cleaning or disinfection) on reprocessing 
protocol efficacy, making it a variable of interest in the current study. 
The objective of this study was to validate the reprocessing of a disposable BVM 
under simulated worst-case use conditions. This was accomplished by investigating i) the 
impact of organic load and post-contamination drying time on reprocessing protocol 
efficacy and ii) the effects of repeated use and reprocessing on BVM functional 
performance. The impact of organic load and post-contamination drying time on 
reprocessing protocol efficacy (Sections 4.3.1 and 4.3.2 respectively) were evaluated with 
the two cleaning validation methods used previously [8]. The effects of repeated use and 
reprocessing on BVM functional performance were measured by tidal volume, a key 
ventilation parameter (Section 4.3.3). 
 
4.2 METHODS AND MATERIALS 
4.2.1. Simulated Worst Case Testing Overview 
Experimental Design 
 This current study expanded on simulated worst-case conditions related to drying 
time, accumulated organic load in disinfectant solutions, and damage accumulation 
during repeated use/reprocessing. The impact of worst-case use conditions was studied in 
two parts: simulated worst-case drying time (Section 4.2.2) and simulated worst-case use 
conditions (Section 4.2.3). The objective of the first study was to examine the impact of 
post-contamination drying time on reprocessing protocol (Figure 4.1) efficacy. The 
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objective of the second study was to evaluate the effects of worst-case reprocessing 
conditions (Figure 4.2), including prolonged post-contamination drying time, on the 
ability of the bleach-based reprocessing protocol to meet disinfection targets. The 
simulated worst-case use testing conditions (Section 4.2.3) are defined as follows: highly 
diluted bleach pH (~11), high organic load (240 mL, equivalent to using a sodium 
hypochlorite solution that has been used in the reprocessing of 80 masks), and prolonged 
post-contamination drying time. A bleach pH of 11 was chosen to represent a worst-case 
condition: extremely low hypochlorous acid presence. The organic load volume was 
chosen to equate to >20% of the total volume of the soiled disinfectant solution, as a 
volume of 10-20% organic load has been shown to significantly impair the chlorine 
activity in other soiling studies [34, 35]. 
 All testing in simulated worst-case conditions (Sections 4.2 and 4.3) utilized the 
reprocessing protocol as mentioned in the introduction (Figure 4.1) and Artificial Mucus 
Soil and Staphylococcus epidermidis (ATCC12228) as the contaminants. The bleach-
based reprocessing protocol involved a 10-minute submersion of the device in a 0.5% 
sodium hypochlorite solution, followed by a 10-minute submersion in non-enzymatic 
detergent (1:10 dish soap to water), 1-minute submersion in ASTM Type I water, and 10-
minute air dry (Appendix C.1): 
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Figure 4.1. Reprocessing Protocol. General bleach-based disinfection protocol utilized 
in an urban Tanzanian hospital. 
 
 
Figure 4.2. Experimental Design for Worst-Case Use Conditions.  
Contaminants and Cleaning Validation Methods 
 Simulated worst-case soiling conditions utilized a mixture of 
Staphylococcus epidermidis and Artificial Mucus Soil (referred to in this paper as ‘soil 
mixture’) [18], which provided cleaning markers for the validation process, including 
protein, total organic carbon, nucleic acids, and carbohydrates. S. epidermidis 
ATCC12228 is gram-positive and commonly found in the human upper respiratory tract 
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and paranasal sinuses as well as on skin, which made it a suitable inoculum species. The 
bacteria were prepared as a 2% transfer of S. epidermidis stock culture in sterile tryptic 
soy broth, producing a total volume of 100 mL (Appendix B.1). These cultures were then 
incubated for 24 hours at 37°C and added in a 1:9 ratio to the Artificial Mucus Soil. This 
mixture was then incubated for 24 hours at 37°C. The Artificial Mucus Soil (Appendix 
B.1) was prepared according to an international standard (ASTM F3208) for the 
validation of cleaning methods for reprocessed medical devices and contained the 
following components: dried pig mucin, casein hydrolysate, sodium chloride, diethylene 
triaminepentaacetic acid, ASTM type I water, potassium chloride, salmon sperm DNA, 
freeze dried egg yolk emulsion, and phosphate buffered saline. 
In both parts of the simulated worst-case testing, once samples reached their 
designated drying time after exposure to the soil mixture, they were immediately tested 
for adenosine triphosphate (ATP) presence and microbial growth or put through a 
reprocessing protocol and checked for ATP presence and microbial growth (Appendix 
B.3). The detection of ATP indicates that the surface tested can support microbial life. 
This method has been demonstrated to be an effective indicator of cleaning and has a 
detection limit of 0.2 mg protein per swab [19]. Sample collection swabs, provided by the 
manufacturer, were inserted into a handheld device that measures bioluminescence. 
According to the manufacturer, the sampled area is considered “clean” if the RLU 
(relative luminescence units) value displayed is less than 100. For this study, a successful 
reprocessing protocol will yield RLU values of less than 100 in all trials. 
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The standard plate count (Appendix B.2), a widely used microbiological 
technique for determining bacteria counts, provided the number of colony-forming units 
(CFUs) and includes the following steps. Surface samples were taken from each PVC 
sample, placed into 10 mL of sterile deionized water (ASTM Type I), and vortexed for 
one minute. From this, a ten-fold serial dilution was performed, spread onto prepared 
agar plates (Tryptic Soy Agar, Remel, Lenexa, KS), and incubated for 24 hours at 37°C. 
CFUs were manually counted and recorded after the incubation period. Results are 
recorded as the ‘log reduction of bacteria’ using Equation 4.1, where CClean is the log 
value of CFUs eliminated from the sample (upon cleaning) and CDry is the log of the 
starting number of CFUs prior to cleaning: 
log reduction in bacteria = log(𝐶𝐷𝑟𝑦) − log (𝐶𝐶𝑙𝑒𝑎𝑛)      (4.1) 
 The Spaulding Classification provides the appropriate disinfection targets for 
reprocessed medical devices [20]. For a semi-critical reprocessed device such as the 
BVM, a 6x reduction in bacteria achieved through high level disinfection (or 
sterilization) is required. 
BVM Units Tested 
 The following masks (Table 4.1) experienced different reprocessing conditions 
and levels of physical damage, which were intended to represent the effects of repeated 
use and reprocessing. Two BVM designs, which are referred to as ‘Mask 1 and Mask 2’, 
were chosen due to their wide use in hospitals around the world. A third brand (Mask 3) 
was made of the same material as Masks 1 and 2 and was used to provide sample 
coupons for the drying time studies. 
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Table 4.1. BVM Units Tested. 
BVM 
Unit 
Images Description 
Mask 
1A 
 
            (1)                    (2)                                   (3) 
Comprised of a 
cushioned PVC face 
mask (1,2), one-way 
silicone rubber valve, 
and PVC self-
inflating bag (3). 
New models 
used.USE, PERFORM 
Mask 
1R 
Same model as Mask 
1 but underwent 20 
reprocessing cycles 
with 24 hours of 
post-contamination 
drying.PERFORM 
Mask 
1PD 
 
Mask 
1FD 
 
Mask 1PD had a one 
inch slit along the 
bottom of cuff so 
partial deflation 
occurred. Mask 1FD 
had a one inch slit on 
side of cuff, 
rendering it 
deflated.PERFORM 
Mask 
1A 
 
Abraded with P40 
grit sandpaperD until 
significant visible 
damage was 
observed (no 
puncturing).PERFORM 
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Mask 
2B 
 
(1)                    (2)                                    (3) 
Comprised of a 
cushioned PVC face 
mask (1,2), one-way 
liquid silicone rubber 
valve, and SEBS 
self-inflating bag (3). 
New models 
used.PERFORM 
Mask 
3C 
 
Comprised of PVC, 
featuring a rigid, 
non-rebreathing 
valve.DRY 
A Laerdal® Adult Mask #4, Laerdal Medical AS, Wappingers Falls, NY 
B Ambu® SPUR® II, Ambu Inc., Columbia, MD 
C Model Life-100, Life Corporation, Milwaukee, WI 
D Shopsmith® 4.5 x 5.5 in L 40-Grit Commercial Sanding Sheets, RLF Brands, Dayton, 
OH 
DRY Used in Simulated Worst-Case Drying Time testing 
USE Used in Simulated Worst-Case Use Conditions 
PERFORM Used in Bag-Valve-Mask Functional Performance 
 
4.2.2. Simulated Worst-Case Drying Time 
Sample Preparation 
 Eighteen sample coupons were prepared. Nine samples underwent drying 
and subsequent cleaning with the reprocessing protocol (Figure 4.1). These samples are 
referred to as ‘dried and reprocessed’. Six samples underwent drying only (referred to as 
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‘dried only’), and 3 samples served as the negative control. The negative controls were 
contaminated but did not undergo any drying or cleaning and were used as benchmarks 
for comparison with the cleaned samples. Coupons from Mask 3 were cut into 8 cm2 
samples and sonicated in full-strength 5.25% sodium hypochlorite (Clorox® bleach, The 
Clorox Company, Oakland, CA) for 20 minutes. Following this, they were soaked in 
filtered deionized water (ASTM Type I) for 10 minutes and allowed to dry in a sterile 
environment for 10 minutes. 
After the final incubation of the soil mixture as described in Section 4.2.1, 0.2 mL 
of the bacteria and Artificial Mucus Soil were spread over 8 cm2 on each sample using a 
plate spreader and dried for 0 hours, 4 hours, 8 hours, and 24 hours in ambient conditions 
in a class II biosafety cabinet. These times and soil mixture volume were chosen based on 
drying times used in relevant literature [31] and results from a preliminary drying time 
study in which coupons were visually wet for up to 240 minutes and were visually dry 
after 1440 minutes. In that preliminary study, sample coupons were inoculated with 0.4 
mL of soil mixture over 8 cm2. Half of the sample coupons (4 cm2) were designated for 
sampling—one half for ATP testing and one half for standard plate count. 
4.2.3. Simulated Worst-Case Use Conditions 
Sample Preparation and Contamination 
Thirteen disposable units of Mask 1 were selected, three of which served as the 
negative control (no cleaning or disinfection). These masks came in sealed bags, which 
were opened in a sterile environment immediately before use. The same 1:9 mixture of 
Staphylococcus epidermidis and Artificial Mucus Soil as described in Section 4.2.1 was 
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prepared, producing a total volume of 2500 mL. After the soil mixture was incubated for 
a final time (24 hours), each mask was submerged in the mixture for 5 minutes before 
drying for 12 hours. Following the drying time, a total of 10 masks underwent the 
reprocessing protocol (Figure 4.1). Five masks were reprocessed using a sodium 
hypochlorite solution of pH >11 while the remaining five were subjected to a sodium 
hypochlorite solution (pH >11) with 24% (vol/vol) of added organic matter (Artificial 
Mucus Soil). The masks subjected to the sodium hypochlorite and organic matter are 
referred to as the ‘With Organic Load’ and were not introduced to the disinfectant 
solution until 10 minutes after the organic matter had been added to the sodium 
hypochlorite. This was done to allow the pH to stabilize after organic load was added 
(Appendix B.4). Half of the inside of each mask was designated as the sample collection 
area (173 cm2 per half): one half for ATP testing and one half for the Standard Plate 
Count. 
4.2.4. Bag-Valve-Mask Use and Functional Performance 
BVM Ventilation Parameters and Technique 
The BVM provides positive pressure ventilation during manual resuscitation. 
There are two key measures of ventilation performance, as established by the American 
Heart Association and European Resuscitation Council: tidal volume and ventilation rate 
[21, 22]. Tidal volume is measured in milliliters of air and corresponds to the amount of 
air delivered to the patient airways as the BVM is squeezed. For the purposes of this 
research, the ventilation rate and duration were kept constant, and the tidal volume was 
provided by manikin simulation software. Successful ventilation is dependent upon 
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proper patient positioning and assumes no physical obstructions are present in the 
patient’s airways. 
Repeated use and reprocessing have the potential to impair the BVM’s ability to 
function as intended; this is an area that has largely been unexplored. The anticipated 
effects of repeated reprocessing are related to key characteristics of ventilation. Proper 
ventilation is accomplished first through tilting of the patient’s head and lifting of the 
chin [23]. In the performance test setup, the manikin’s head was fully tilted back so that 
the patient airway was open. Second, the mask must achieve an adequate seal. Use of the 
two-handed E-C clamp in this study (Figure 2.3) was not only representative of common 
clinical technique but also recommended due to the improved sealing of the mask it 
provides [21, 24-26]. The last key consideration is the volume of air delivered, which is  
influenced by squeeze rate, bag size, and hand positioning [27]. During BVM use, the 
provider should be able to deliver a tidal volume of 400-700 mL of air with each squeeze, 
deliver 10-12 breaths per minute, and observe a chest rise and fall in the patient [21]. In 
the testing setup, markings on the bag provided guidelines for consistent hand placement, 
breaths were delivered over a one second interval at a rate of 10 breaths per minute, in 
accordance with American Heart Association resuscitation guidelines, and manikin chest 
rise and fall was monitored. 
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Figure 4.3. Manikin Resuscitation Set-Up. Left: Two-handed E-C Clamp. Right: One 
handed E-C Clamp. For testing purposes, the configuration on the left was used. 
Resuscitation Manikin and BVM Models 
The Laerdal® SimMan® 3G manikin (Laerdal USA, Wappingers Falls, NY, 
USA) and LLEAP software (version 6.6.0.3884) were utilized in the tidal volume 
experiments. Manikin lung compliance was set to 0, which is recommended for 
performing CPR. The manikin was programmed to have a heart rate of 20 beats per 
minute and blood oxygen saturation of 79% to mimic conditions of a patient under 
cardiac/respiratory arrest. The static airway compliance has been found to be lower than 
that of human lungs due to the lung reservoir material not having the same elasticity as 
human lung tissue [28]. For these research purposes, the lower lung compliance 
illustrates a possible worst-case condition for a pulmonary fibrosis patient [29]. The 
following BVM units were tested: Mask 1 (n=3), Mask 2 (n=2), Mask 1R (n=3), Mask 
1PD (n=1), Mask 1FD (n=1), and Mask 1A (Table 2.1). Data was recorded over a period 
of one minute to obtain a total of ten readings per BVM unit. 
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4.3 RESULTS 
4.3.1. Simulated Worst-Case Drying Time 
 The negative control samples, as expected, had RLU values greater than 100 
(Table 4.2). The inoculum count (Appendix A.1) for this experiment was 1.27E5 
CFU/mL of S. epidermidis. The negative control samples had 1.05E4 CFU/mL. All ‘dried 
only’ samples had RLU values greater than 100, with the exception of one, indicating that 
those surfaces still had sufficient levels of bioburden present. All ‘dried and reprocessed’ 
samples had RLU values close to 0 and exhibited no bacterial growth (Table 4.3). 
Table 4.2. Simulated Worst-Case Drying Time ATP Results. 
 Sample 
ATP Value (RLU) Target 
met? Trial 1 Trial 2 Trial 3 
 Negative 
control 
281 249 330 N/A 
Dried only 
4 hours 175 148 n/a No 
8 hours 194 77 n/a No 
24 hours 153 252 n/a No 
Dried and 
reprocessed 
4 hours 1 3 1 Yes 
8 hours 0 0 0 Yes 
24 hours 0 0 0 Yes 
 
Table 4.3. Simulated Worst-Case Drying Time Standard Plate Count Results. 
 Sample 
Log Reduction in Bacteria* 
Target 
met? 
Trial 
1 
Trial 2 Trial 3 
 Negative 
control 
0 0 0 n/a 
Dried only 
4 hours 
No bacteria growth on all 
plates 
Yes 
8 hours 
24 hours 
4 hours 
 57 
Dried and 
reprocessed 
8 hours 
24 hours 
*As calculated using Equation 4.1 
4.3.2. Simulated Worst-Case Use Conditions 
 The negative control samples, as reflected in the average, had RLU values greater 
than 100 (Table 4.4). This was the case for all negative control samples, which were all 
above 163 RLU (Appendix A.4). The positive controls had an average RLU value of 1.4, 
which met the disinfection target. The ‘With Organic Load’ masks had an average RLU 
value of 1.6, which also met the disinfection target. Bacteria growth was observed for the 
negative control, as expected, but not for the positive controls or ‘With Organic Load’ 
BVM (Table 4.5). The inoculum concentration (Appendix A.1)was 3.09E5 CFU/mL. 
Table 4.4. Simulated Worst-Case Use Conditions ATP Results. 
Sample Average ATP Value (RLU) Target met? 
Negative 
controls 
672 N/A 
Positive controls 1.40 Yes 
With Organic 
Load 
1.60 Yes 
 
Table 4.5. Simulated Worst-Case Use Conditions Standard Plate Count Results. 
 
Sample 
Log Reduction in Bacteria* 
Target met? 
Trial 1 Trial 2 Trial 3 
Negative 
controls 
0 0 0 N/A 
Positive controls 
No bacteria growth on all plates 
Yes 
With Organic 
Load 
Yes 
*As calculated using Equation 4.1 
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4.3.3. Bag-Valve-Mask Functional Performance 
 The average tidal volumes and corresponding standard deviations (Appendix A.5) 
fell within the target range of 400 to 700 mL for all masks except for the partially inflated 
and fully deflated masks (Figure 4.4). Mask 1 (Appendix A.6) and Mask 1R (Appendix 
A.7) had roughly a 2% difference in tidal volume. Mask 1A (Appendix A.9) and Mask 2 
(Appendix A.8) were able to meet tidal volume targets as well. However, the Mask 1PD 
and Mask 1FD (Appendix A.9) did not meet the minimum threshold for tidal volume 
delivery. The partially deflated mask (Mask 1PD) produced tidal volumes above the 
minimum threshold occasionally, but its average tidal volume was below the target range. 
Most tidal volumes for Mask 1FD were nearly zero. Mask 1 and Mask 2 maintained an 
average tidal volume within the range of 400 to 700 mL. Summarized tidal volume 
statistics can be found in Table 4.6. There is no significant difference between the tidal 
volume measured for masks used in a new condition or after 20 cycles of reprocessing 
(Mask 1 vs. Mask 1R, t-test, p=0.479). There is also no significant difference between the 
tidal volume measured for different masks used in a new condition (Mask 1 vs. Mask 2, t-
test, p=0.900). 
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Figure 4.4. Average Tidal Volume Comparison. 
 
Table 4.6. Average1,2 Tidal Volume Comparison. 
Mask Mean Tidal Volume (mL) (Standard Deviation), [Range] 
1 604.7 (10.3), [597-616] 
1R 592.6 (24.4), [576-621] 
2 583.4 (121.8), [497-670] 
1A 559 
1FD 22 
1PD 382 
1 Data for Masks 1, 1R, and 2 represent the average of three trials of 10 repeated 
measures of tidal volume 
2 Data for Masks 1A, 1FD, 1PD represent the average of one trial of 10 repeated 
measures of tidal volume 
 
4.4 DISCUSSION 
4.4.1. Simulated Worst-Case Drying Time 
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The objective of this investigation was to study the impact of post-contamination 
drying time on reprocessing protocol efficacy. No bacterial growth was observed for S. 
epidermidis when drying times of 4 hours or more were used, which was the case for 
both ‘Dried Only’ and ‘Dried and Reprocessed’ samples (Table 4.3). Previous work with 
this reprocessing protocol showed that the protocol was able to meet disinfection targets 
for Mask 3, which had a post-contamination drying time of 15 minutes (when bacteria 
were confirmed to be alive) [8]. One conclusion that could be drawn from this is that the 
protocol meets cleaning and disinfection targets, regardless of the drying time and vitality 
of the S. epidermidis. However, it is important to note that the increased drying times 
made the sampling of physical debris more challenging, which could have contributed to 
the lack of observed bacterial growth. In regard to the variance in ATP values for the 
‘dried only’ sample, this is likely due to the slightly uneven spread of the soil because of 
PVC’s high surface tension and curvature of the mask the samples were cut from. 
Reprocessing these BVM by soaking in the 0.5% sodium hypochlorite and 10% 
detergent solutions was effective for achieving high-level disinfection, regardless of post-
contamination drying time. Residual bioburden was present after extended drying times, 
but there was an absence of detectable ATP after 20 minutes of exposure time to the 
reprocessing solutions (Table 4.2). These findings were consistent with previous studies 
[30, 31] investigating the consequences of soil drying on stainless steel instruments and 
endoscopes due to delayed reprocessing from 30 minutes up to 24 hours. Alfa, et al. 
found that using only a water flush during cleaning, in the absence of agitation or 
scrubbing, was ineffective for removing dried soils and bacteria during endoscope 
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reprocessing [31]. However, soaking for 20 minutes in glutaraldehyde was effective for 
achieving high-level disinfection. Lipscomb, et al. found that any amount of post-
contamination drying time of prion-infected tissue, even as little as 15 minutes, was 
detrimental to the cleaning process [30]. This is likely due to the nature of the 
contaminant, PrPSc (scrapie prion), an abnormal type of normal cellular protein. The 
scrapie prion is highly aggressive in its surface adsorption abilities [32, 33]. It is apparent 
that post-contamination time can negatively impact reprocessing protocol performance. 
As demonstrated in the current study and work by Alfa, et al., bioburden can be 
successfully removed if the right disinfectants are used for appropriate lengths of time. 
4.4.2. Simulated Worst-Case Use Conditions 
The simulated worst-case use conditions for organic load in the cleaning solutions 
involved adding Artificial Mucus Soil to a sodium hypochlorite solution (5 000 ppm). 
This investigation demonstrated that the bleach was effective in eliminating bioburden 
from the masks, despite the presence of nearly 25% (vol/vol) added organic matter (Table 
4.4 and Table 4.5). Bloomfield and Miller found decreased disinfection performance of 
sodium hypochlorite (2,500 ppm) in the presence of human plasma and three bacterial 
strains when 20% (vol/vol) plasma was added to the disinfectant solution (Table 4.7). 
When this volume of plasma was added to the sodium hypochlorite, high level 
disinfection was not achieved in two out of the three bacteria suspensions [34]. 
One study by Best et al. [35] examined the efficacy of a sodium hypochlorite 
solution (5,000 ppm) with added organic matter in the form of tryptic soy broth (TSB) 
and human serum (Table 4.7). Both suspensions and carrier surfaces were tested for the 
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presence of bacteria [35]. Only the suspension achieved high-level disinfection when 
TSB was the organic load involved. However, both the carrier surfaces and suspensions 
failed to meet high-level disinfection when human serum was the organic load [35]. 
Although the bacteria-to-disinfectant ratio was smaller than that in the simulated worst-
case use testing for the BVM, the contact time was ten-fold shorter in Best et al.’s study, 
compared with the current BVM reprocessing study. These study conditions are not 
identical to the current BVM reprocessing study, but results demonstrated that achieving 
nearly a 6x reduction in bacteria under 10% (vol/vol) organic load is feasible with a 5,000 
ppm sodium hypochlorite solution. In other studies, 5,000 ppm sodium hypochlorite 
solutions have been widely proven and accepted for killing pathogenic material found in 
bodily fluids such as blood, making them a suitable choice for achieving high-level 
disinfection [36, 37]. 
 
Table 4.7. Organic Load Summary 
Reference 
Bleach 
Concen. 
(ppm) 
Contact 
Time 
(min) 
Organic 
Load 
(% 
vol/vol) 
Bacterial Species 
High-Level 
Disinfection 
Achieved? 
Zemitis, 
Harman, 
Hargett, and 
Weinbrenner 
(current 
study) 
5 000 10 
Artificial 
Mucus Soil 
(24%) 
Staphylococcus 
epidermidis 
(ATCC12228) 
Carrier 
Surface 
(PVC) 
YES 
Best et al. 
[AV] 
5 000* 1 
TSB 
(10%) 
Listeria innocua 
(LCDC 86-417) 
Suspension YES 
Carrier 
Surface 
(Steel disc) 
NO 
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Human 
serum 
(10%) 
Listeria 
monocytogenes 
(LCDC 88-702 
Suspension NO 
Carrier 
Surface 
(Steel disc) 
NO 
Bloomfield 
and Miller 
[AU] 
2 500 
10 
Human 
plasma 
(10%) 
Staphylococcus 
aureus 
(NCTC 4163) 
 
Suspension YES 
Pseudomonas 
aeruginosa 
(NCTC 6570) 
Suspension YES 
Escherichia coli 
(NCTC 8196) 
Suspension YES 
10 
Human 
plasma 
(20%) 
Staphylococcus 
aureus 
(NCTC 4163) 
 
Suspension NO 
Pseudomonas 
aeruginosa 
(NCTC 6570) 
Suspension NO 
Escherichia coli 
(NCTC 8196) 
Suspension YES 
*solution also contained 5% methylethanol 
 The two most important factors in disinfectant performance are 
concentration and contact time [37]. The second study [34] used a sodium hypochlorite 
concentration of 2,500 ppm, which is half the concentration of that used in the current 
BVM reprocessing study and by Best et al [35]. However, its contact time was 10-fold 
higher than that in the first study by Best et al. The sodium hypochlorite solution was 
able to achieve high-level disinfection for all three bacteria species despite a significantly 
lower disinfectant concentration [34]. One final key consideration is the type of bacteria 
used, as some microorganisms are inherently more resistant to disinfectants than others. 
All three studies discussed above used different bacteria species, which makes it 
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challenging to equally compare disinfection outcomes. These studies illustrate the 
interdependent relationship that variables such as disinfectant concentration, contact time, 
bacteria, and organic matter presence have on disinfectant performance. 
4.4.3. Bag-Valve-Mask Functional Performance 
Level of reprocessing and presence of abrasion did not impede the BVM unit’s 
ability to deliver adequate tidal volumes to the manikin. Even with abrasion damage, the 
BVM was highly effective in delivering average tidal volumes within approximately 8% 
to 4% of the new, unused masks (Masks 1 and 2, respectively). While the surface 
abrasions may have impacted the seal, the 8% difference could be attributed to the human 
operator, since hand placement, squeeze rate, and bag size have been found to heavily 
influence tidal volume [27]. Human factor-related variables were constrained in testing as 
much as possible by having care providers use the same hand placement during BVM use 
and by using a metronome to time delivered breaths, but variability between bag squeeze 
rates, even for the same care provider, is difficult to control. The reprocessed masks 
(Mask 1R) achieved average tidal volumes of within <2% of the new, unused masks 
(Masks 1 and 2). 
However, punctures that caused mask deflation to any extent resulted in decreased 
performance due to loss of conformity in the cuff. Based on these data, damage leading to 
decreased functional performance are easily visualized and useful for screening masks 
during reprocessing. One important point to highlight is that while the target tidal volume 
range spans 400 to 700 mL, adequately ventilating the patient could require tidal volumes 
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above or below this range. This is dependent on the patient’s physiopathology, as each 
patient’s conditions before and during BVM intervention can vary [38]. 
4.4.4. Limitations 
These studies provide a framework for simulating worst-case reprocessing 
conditions and evaluating reprocessing protocol efficacy for the reuse of medical devices. 
There are several limitations to note. Several assumptions were made regarding the 
reprocessing conditions. First, ASTM Type I water was used to reduce likelihood of 
water quality effects on the study, which was not the primary focus on the study. Water 
quality may vary, especially in LMIC—understanding the water treatment in use is 
crucial to the reprocessing of medical devices. S. epidermidis ATCC12228, gram-
positive, was chosen as the inoculum species. It is unknown how gram-negative bacteria 
would respond to the same chemical treatment in the tested protocol. Finally, the selected 
soiling conditions mimicked human mucus from a cystic fibrotic patient; in a clinical 
setting, the BVM could be exposed to patient emesis and bacteria from improper 
handling of the device and consequent contamination. The Laerdal® BAG® II BVM was 
used in the protocol efficacy studies, which may not be fully representative of the other 
BVM brands. While it has been shown that BVM functionality does not significantly 
deviate across brands, the microbiological study results may not be generalizable to other 
reprocessed BVM masks due to different mask materials, sizes, and geometries. Finally, 
this study did not examine the effect of human factors, as there is likely variability 
between users performing reprocessing of the BVM. All microbiological and tidal 
volume work was performed by trained biomedical engineering students or medical staff. 
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One final limitation to note is the sampling of bacteria discussed in Section 4.4.1. 
No bacterial growth was seen for samples that were dried and reprocessed, as well as 
samples that were dried but did not undergo reprocessing. The standard plate count 
method was used to quantify bacterial growth, which involved sampling the area of 
interest with a sterile cotton tipped swab and aseptically transferring the swab to a 
dilution tube and vortexing for one minute. The challenge with the increased drying time 
was that it became more difficult to physically remove debris from the sample coupon. 
The ATP swabs were coated in a liquid solution, which made sampling of surfaces easier. 
Visual inspection verified this, as the sampled side no longer had visible debris. 
However, the dry cotton swab could only remove so much physical debris from the 
sample surface without breaking due to the increased effort required during sampling. 
 
4.5 CONCLUSION 
These studies provided a holistic framework for validating reprocessing protocols 
under simulated worst-case conditions. While prolonged post-contamination drying times 
and high organic loads can negatively impact reprocessing protocol performance, 
successful removal of bioburden is possible if the right disinfectants are used over 
appropriate contact times. The sodium hypochlorite solution proved to be effective in 
achieving high-level disinfection regardless of the simulated worst-case conditions. 
Repeated reprocessing and presence of abrasion did not impede the BVM unit’s ability to 
deliver adequate tidal volumes. Impactful future areas of investigation include examining 
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the impact of human factors, specifically through usability studies, on user compliance 
with the current BVM reprocessing protocol.  
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CHAPTER FIVE 
INFLUENCE OF HUMAN FACTORS ON REPROCESSING 
5.1 INTRODUCTION  
 Human factors engineering (also known as usability engineering) involves the 
study of human interactions with technology and the influence of user interface design on 
these interactions [1]. In the reprocessing of medical devices, the aim of human factors 
engineering is to demonstrate that a device can be safely and effectively reused. This 
includes understanding who is performing reprocessing (referred to as the “user” in this 
paper), under what conditions the reprocessing is being performed, and what the details 
of the reprocessing procedure are [1]. Identification of critical tasks, which are tasks that 
must be performed correctly for a process to be safe and effective, can be accomplished 
through a task analysis [1]. This analytical approach divides processes into discrete 
components so that user errors can be identified, as well as potential consequences of 
those errors [1]. 
 The FDA requires validation studies for cleaning and sterilization of medical 
devices, with regulations covering both reusable devices and single-use devices [1-3]. 
Poorly written reprocessing instructions can hinder user compliance with those 
instructions, especially for manual cleaning steps, which can increase the risk of 
inadequate cleaning and negatively impact patient safety [4, 7, 8]. As described in 
Chapters 2 and 3, a bleach-based reprocessing protocol taken from an urban Tanzanian 
hospital successfully met disinfection targets for the bag-valve-mask (BVM), a 
resuscitation device commonly reused in low-resource hospitals [5]. However, it is 
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unknown how user variability contributes to the ability to achieve appropriate 
disinfection for the BVM since the protocol has not been validated from a human factors 
perspective. It is likely that the current reprocessing instructions may confuse someone 
who is untrained or unfamiliar with reprocessing the device, as the written steps lack 
clarity and do not provide detailed direction. Given that BVM are classified as semi-
critical reprocessed devices due to their contact with mucous membranes [6], they require 
high-level disinfection (6-log reduction in bacteria) during reprocessing. Effective 
disinfection can be compromised if reprocessing steps are omitted or completed 
incorrectly. 
 The broad objective of this study is to design a usability study to assess protocol 
compliance and task efficiency related to BVM reprocessing. This was accomplished by 
1) creating a task analysis for BVM reprocessing, 2) defining key study output variables, 
and by 3) establishing a usability study procedure that assesses defined study outputs. 
 
5.2 MATERIALS AND METHODS 
Bag-Valve-Mask Reprocessing Protocol 
 The bleach-based reprocessing protocol (Appendix C.1) described in Chapters 2-4 
includes a 10-minute submersion of the device in a 0.5% sodium hypochlorite solution, 
followed by a 10-minute submersion in non-enzymatic detergent (1:10 dish soap to 
water), 1-minute submersion in ASTM Type I water, and 10-minute air dry: 
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Figure 5.1. Reprocessing Protocol. General bleach-based decontamination protocol 
utilized in an urban Tanzanian hospital. 
Task Analysis 
 A task analysis (Appendix C.1) was developed for the bleach-based reprocessing 
protocol, which is to be filled out by the researcher as they observe the study participant. 
Sub-tasks for each of the nine main tasks in the protocol have the option to be ranked as 
0, 1, or 2: 0 indicates the task was not completed at all, 1 indicates the task was 
completed with some difficulty, and 2 indicates that the task was completed with ease. 
Additionally, each task contained a designated space for general comments or 
observations. The utility that this approach offers is a quantitative analysis of user 
protocol compliance during reprocessing. While the task analysis provides some insight 
into user behavior, other data collection methods are needed to gain a holistic 
understanding of errors made during reprocessing and root causes. 
Key Study Variables 
 This systematic documentation of reprocessing tasks and sub-tasks also led to the 
identification of key study variables for BVM reprocessing. These variables can be 
simplified into three categories (Table 5.1): level of protocol compliance, task efficiency, 
and task difficulty level. Protocol compliance becomes a key variable when manual 
Soiled 
Device 
Soak in 
0.5% 
sodium 
hypochlorit
Soak in 
soapy 
water 
(1:10) 
Submerge 
in water 
Air 
dry 
10 min 10 min 1 min 10 min 
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cleaning is involved in reprocessing. Extremely low compliance levels have been 
demonstrated in endoscope reprocessing, which are the main cause of endoscopy-
acquired infections [7]. However, when the right protocol design changes are 
implemented, compliance rates can significantly improve. This was demonstrated in a 
study where improvements to endoscope reprocessing instructions using effective human 
factors design principles nearly doubled protocol compliance [8]. In the current study, the 
level of compliance is primarily assessed through a task analysis, as described in the 
previous section. 
Table 5.1. Key Study Variables. 
 Captured by 
Category Item Camera Observation 
Protocol 
Compliance 
Device disassembly prior to cleaning X  
Soaking time of BVM components in 
each solution 
X  
Number of steps and sub-steps that 
were completed correctly 
X  
Full submersion of device in each 
solution 
X  
Lid placement over bin in final step X  
Proper surgical glove disposal  X 
Surrounding surface cleaned with 
bleach and cloth 
X  
Task 
Efficiency 
Time it takes to complete each step X  
Number of times participant looks at 
instructions for each step 
 X 
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Participant method for time-keeping X X 
Difficulty 
Level 
Participant facial expressions during 
specific steps 
 X 
Number and type of questions 
participants asked 
X  
 
 Task efficiency was selected as a variable of study due to the quick turnaround 
times required in hospital reprocessing operations. This variable is measured by timing 
each of the nine tasks in the protocol (Appendix C.2). Lastly, task difficulty is assessed 
through a verbal questionnaire at the end of the study (Appendix C.2), in which responses 
are recorded on a five-point Likert scale. This questionnaire addresses the how confident 
the participant felt in their ability to reprocess the device, how thoroughly they thought 
they cleaned the device, and how straightforward the protocol instructions appeared to 
them. Additionally, participant facial expressions and comments are noted throughout the 
study, which can confirm the difficulty level of the steps. These three key variables form 
the framework for the usability study design. 
Usability Study Participant Selection 
Recruitment involves the posting of flyers on Clemson’s campus and sending e-
mails to Clemson students and faculty. Those who wish to participate will be screened 
over the phone or via e-mail, and their name, age, gender, phone number, and e-mail 
address will be collected. Approximately 10-15 adults aged 18 years and older who can 
read, write, and speak in English will be selected for participation. This number of 
participants will allow the research team to reach a “saturation point” in data collection, 
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where beyond this number, little to no new information about the process would be 
gathered. The “saturation point” marks the end of the study and is determined when no 
new insight is gathered in studying the behavior of one to two participants, consecutively, 
compared to what was learned from the first few participants. Once this point has been 
reached, an additional participant would add little to no value because researchers can 
predict how future participants may behave with the sufficient level of information they 
have already gathered. The participant questionnaire at the end of the study will gather 
information on their level of formal lab training or experience working with chemical 
handling or sanitation. The extent of formal liquids handling training and experience is 
important to capture, as these factors could impact their ability to reprocess the BVM. 
Usability Study Procedure 
 Each participant is assigned a participant ID, which will disassociate their name 
with their data. Their data will only be available to the research team and will be stored 
on a secure dual-authentication file-sharing and storage platform (Box, Box, Inc., 
Redwood City, CA). Key study output variables will be assessed using a combination of 
video recording, direct observation, and in-person interviews. A video camera located 
above the workspace will record the participant’s actions throughout the reprocessing 
task without recording their face. Before starting, each participant will be given full detail 
of the study, including potential risks (which there are none of). Upon signing the 
informed consent form, participants will be tasked with reprocessing a fully assembled, 
unused BVM at a designated workstation (Figure 5.2) with reprocessing instructions. 
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Figure 5.2. Workstation Set-Up 
 Participants will put on surgical gloves before handling the BVM, treating the 
device as if it has been used. On the workstation counter, three bins will be laid out side 
by side labeled “Bleach”, “Soapy Water”, and “Clean Water.” Bleach was not used in 
this study due to participant safety considerations, so the “Bleach” solution contains dyed 
water. Additionally, the main focus of this study is on protocol compliance rather than the 
ability of the protocol to meet disinfection targets; this will be addressed in a future study. 
In the workspace, all necessary items (Figure 5.2) are available to the participant, which 
include the same BVM unit from Chapter 4, all reprocessing chemicals, and surgical and 
utility gloves as specified in the original reprocessing protocol (Table 5.2). Once the 
participant has finished reprocessing the device, a verbal follow-up interview will be 
completed by one researcher. Additionally, participant feedback for protocol 
improvement will be requested. 
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Table 5.2. Study Materials. 
Item Brand/Type 
Quantity per 
Participant 
Bag-valve-mask unit 
Laerdal® BAG II® and Adult Mask 
#4 
(referred to as Mask 1) 
1 
Liquid soap Dawn® Ultra 
Diluted 1:10 
solution 
Tap water n/a n/a 
Simulated bleach 
solution 
Dyed water 5000 mL 
Utility gloves VersaPro™ Latex-Free 1 pair 
Surgical gloves VWR™ Microgrip® Purple Nitrile® 
1 pair (multiple 
sizes available) 
Large bins and lids 
Sterilite® (28 qt; 23” L, 16.25” W, 6” 
H) 
3 
Wiping cloth 
Vileda Professional® MicroTuff Base 
Microfiber Cloth 
1 
Timer n/a 1 
Calculator Texas Instruments 1 
Pen and paper n/a 1 
Video camera, 
memory card 
n/a 1 
Printed 
decontamination 
protocol 
n/a 1 
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5.3 CONCLUSION 
 While the bleach-based reprocessing protocol proved effective in eliminating 
bioburden, it is unknown how human factors variables may impact the protocol’s ability 
to meet disinfection targets as established by the FDA. As discussed in the previous 
sections, study findings will include the identification of protocol steps with high 
between-user variability and steps that cause confusion or mistakes. Ultimately, the 
information gathered from the usability study will not only pinpoint variations in the 
reprocessing of the BVM but will also inform improvement measures for the current 
reprocessing protocol and aid in the development of future protocols. Current efforts 
include recruiting potential study participants, pending IRB approval. Looking ahead to 
the future of this body of work, the next phase may involve comparing the original 
reprocessing protocol to an improved version and assessing the ability of each to meet 
disinfection targets for the BVM. 
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CHAPTER SIX 
ENGINEERING SIGNIFICANCE AND CONCLUSIONS 
 The broad objective of this thesis was to develop and validate a reprocessing 
protocol for single-use devices (SUDs) commonly reused in low- and middle-income 
countries (LMIC). In these studies, the bag-valve-mask (BVM) was the primary SUD of 
interest. This objective was accomplished by fulfilling four aims: 1) document 
reprocessing practices in a tiered healthcare system; 2) develop quantitative cleaning 
validation methods for reprocessing; 3) evaluate reprocessing protocols in simulated 
worst-case scenarios; and 4) define human factors affecting BVM reprocessing. Chapter 
2 describes the findings that fulfill Aim 1, Chapter 3 addresses Aim 2, Chapter 4 
addresses aim 3, and Chapter 5 addresses aim 4. 
Aim 1: Document reprocessing practices in a tiered healthcare system. 
 Aim 1 was fulfilled using data acquired from in-person interviews with various 
hospital personnel in Tanzania. These hospital interviews led to the identification of 
commonly reused SUDs including electrosurgical instruments, bag-valve-masks, and 
operating gowns. Most of the hospitals followed a generalized decontamination protocol 
for SUDs without electrical components. None of the hospitals reported use of inspection 
or screening processes prior to reuse and in many cases, SUDs were continually reused 
until malfunctions occurred. This investigation reveals a clear need to develop and 
validate SUD reprocessing procedures to ensure adequate decontamination of such 
devices and reduce the risk of malfunction during use. 
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 The contributions from this aim provide a glimpse of medical device reprocessing 
operations for a tiered healthcare system, for both urban and rural hospitals. This 
systematic documentation of unregulated reprocessing practices (Table 2.3) is a first step 
toward informing policies for safely reusing medical devices in hospitals throughout 
Tanzania and training biomedical technicians/engineers to provide support for such 
practices. Collaboration with Tanzanian universities is critical to furthering the 
understanding of reprocessing practices across the region and in successfully developing, 
validating, and implementing reprocessing protocols, as they are the ones who will 
provide direct support to the hospital reprocessing operations and gain firsthand insight in 
these areas. 
Aim 2: Develop quantitative cleaning validation methods for reprocessing. 
 Aim 2 was fulfilled by investigating three different residual bioburden analytical 
methods and assessing the efficacy of five reprocessing protocols applied to the BVM, 
which were representative of the varied practices observed at LMIC hospitals. Simulated 
worst-case contamination following an international standard for the validation of 
reprocessing medical devices was used. The ATP detection and standard plate count 
methods were found to be suitable for residual bioburden assessment due to their 
accuracy and ability to produce quantifiable results. Both are widely used and accepted 
for cleaning validation. The data support positive decontamination outcomes using the 
bleach-based reprocessing protocol currently implemented in some Tanzanian hospitals. 
Despite this, it was found that design features of the BVM mask presented challenges to 
cleaning and drying for some decontamination protocols. 
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Aim 3: Evaluate reprocessing protocols in simulated worst-case scenarios. 
 Aim 3 was fulfilled by investigating the impact of organic load and post-
contamination drying time on reprocessing protocol efficacy, and the effects of repeated 
use and reprocessing on BVM functional performance, to ensure safe BVM reuse. It was 
found that the bleach-based reprocessing protocol was effective after a post-
contamination drying time up to 24 hours, in highly alkaline pH solutions, and with 
roughly 25% (vol/vol) added organic load (Artificial Mucus Soil). Repetitive 
reprocessing and the presence of surface abrasion did not impede the BVM unit’s ability 
to deliver adequate tidal volumes to the manikin. 
Aim 4: Define human factors affecting BVM reprocessing. 
 Aim 4 was fulfilled by creating a task analysis for BVM reprocessing, defining 
key study output variables, and by establishing a usability study procedure that assesses 
defined study outputs. Three key variables of interest were identified for the usability 
study: protocol compliance, task efficiency, and task difficulty level. The task analysis 
detailed main tasks and sub-tasks for reprocessing of the BVM and provided a 
quantitative way to assess user protocol compliance. Data collection methods included in-
person Likert scale questionnaires, direct observation, and video recording. Ultimately, 
the information gathered from the usability study will not only pinpoint variations in the 
reprocessing of the BVM but will also inform improvement measures for the current 
reprocessing protocol and aid in the development of future protocols. 
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Conclusion 
 In the broader scheme of reprocessing, this body of work provides a 
comprehensive framework for validating reprocessing protocols for single-use medical 
devices while keeping resource constraints in mind. Hospitals in low-resource areas can 
follow a similar approach to validate and establish reprocessing protocols for the reuse of 
their devices. While the validation work described in this thesis may be useful to LMIC 
hospitals, it can be extended beyond the low-resource setting. This body of work utilized 
standards and accepted practices that are consistent with cleaning validation required by 
the FDA and supported by AAMI [2-5]. For example, the experimental design and 
selection of clinically relevant soil for the validation studies was heavily influenced by 
AAMI guidelines for cleaning reusable medical devices [1]. Disinfection targets for the 
BVM were based off the Spaulding Classification outlined in FDA documents [2]. The 
worst-case soil mixture was prepared according to an international standard (ASTM) for 
validation of cleaning methods for reusable medical devices [3]. Finally simulated worst-
case functionality testing was carried out in efforts to define safe limits of device reuse, 
as required by the FDA in validation data in 510(k)s for reprocessed SUDs [4].  
 Certain device design features can negatively impact reprocessing, as seen in 
Chapters 2 and 3. Devices with electrical components were not able to undergo the 
general decontamination protocol due to their inability to be submerged in disinfectant 
(Chapter 2). Consequently, these devices were either thrown out after malfunctioning or 
were attempted to be cleaned through means that may not achieve the required high-level 
disinfection. Several design features of the masks used in Chapter 3 were considered 
reprocessing challenges, including small crevices near the valve attachment, contours on 
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the outside surface, and tight folds inside the mask. These features proved to be 
opportunistic areas for bacteria and physical debris buildup and hampered the ability of 
the alcohol wipe protocol to achieve high-level disinfection. Design features like these 
can become zones of bioburden entrapment and should either be avoided in the design of 
reusable devices or given more attention during reprocessing [5]. 
To conclude, risks and benefits should be appropriately weighed when 
considering whether a device should be used multiple times or just once. Risk of 
infection is an important consideration in the reuse of medical devices. One could pose 
the case that the risk of serious infection transmission with the bag-valve-mask is low 
because it is not in contact with sterile body cavities. As demonstrated in Chapters 2 and 
3, if properly reprocessed, the BVM will be appropriately disinfected and functionally 
safe for the next user. However, in cases where the patient has a significant risk of being 
exposed to highly pathogenic agents (such as prions), having a disposable device or 
disposable component to the device may be safer for the patient and healthcare personnel.  
 87 
REFERENCES 
1) AAMI Standard TIR30:2011, “A compendium of processes, materials, test methods, 
and acceptance criteria for cleaning reusable medical devices,” Association for the 
Advancement of Medical Instrumentation, Arlington, VA, 2011. 
2) FDA Guidance Document, “Reprocessing Medical Devices in Health Care Settings: 
Validation Methods and Labeling,” Food and Drug Administration, Silver Spring, 
MD, 2015. 
3) ASTM Standard F3208, 2017, "Selecting Test Soils for Validation of Cleaning 
Methods for Reusable Medical Devices," ASTM International, West Conshohocken, 
PA, 2017, DOI: 10.1520/F3208-17, www.astm.org. 
4) FDA Guidance Document, “Medical Device User Fee and Modernization Act of 
2002, Validation Data in Premarket Notification Submissions (510(k)s) for 
Reprocessed Single-Use Medical Devices,” Center for Devices and Radiological 
Health, Silver Spring, MD, 2006. 
5) Patel, A., Pope, J. and Neilson, M. Design Considerations for Medical Device 
Manufacturers. (2012). AAMI Horizons, pp 73-75. 
  
 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
  
 89 
Appendix A 
 
Raw Data for Statistical Analysis 
 
Table A.1. Inoculum Counts for Microbiological Studies 
 
Study Inoculum Count 
Residual Bioburden Analyses (Chapter 3) 1.22E7-2.61E7 CFU/mL 
Simulated Worst-Case Drying Time 
(Chapter 4) 
1.27E5 CFU/mL 
Simulated Worst-Case Use Conditions 
(Chapter 4) 
3.09E5 CFU/mL 
 
 
Table A.2. Residual Bioburden Analyses Standard Plate Count Results Trial 1. CFU 
counts for the bag-valve-mask for trial 1 are listed in the table below. 
 
 Plate 
Dilution 
Count 
1 
Count 
2 
Avg. 
Count 
Concentration 
[bacteria/swab-
mL] 
Log 
bacteria 
Log 
reduction 
Negative 
Control 
0 178 184 181 181000000 8.3 0 
Water 
Rinse 
0 32 37 34.5 34500 4.5 3.7 
Alcohol 
Wipe 
1 0 0 0 0 0 8.3 
Soap 
and 
Bleach 
1 0 0 0 0 0 8.3 
Positive 
Control 
1 0 0 0 0 0 8.3 
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Table A.3. Residual Bioburden Analyses Standard Plate Count Results Trial 2. CFU 
counts for the bag-valve-mask for trial 2 are listed in the table below. 
 
 Plate 
Dilution 
Count 
1 
Count 
2 
Avg. 
Count 
Concentration 
[bacteria/swab-
mL] 
Log 
bacteria 
Log 
reduction 
Negative 
Control 
0 146 144 145 14500000 7.2 0 
Water 
Rinse 
0.01 49 96 72.5 7250 3.9 3.3 
Alcohol 
Wipe 
0.01 49 96 72.5 7250 3.9 3.3 
Soap 
and 
Bleach 
1 0 0 0 0 0 7.2 
Positive 
Control 
1 0 0 0 0 0 7.2 
 
Table A.4. Simulated Worst-Case Use Conditions ATP Results. 
 
Sample 
ATP Value (RLU) 
Replicate 
1 2 3 4 5 
Negative 
controls 
668 638 709 -- -- 
Positive controls 2 4 0 0 2 
With Organic 
Load 
1 1 1 2 2 
 
 
Table A.5. Summary: Average Tidal Volume Data. Tidal volumes were recorded for 
each mask condition during functionality testing. 
 
Mask 
Condition 
Average Tidal Volume (mL) Mean Tidal Volume (mL) 
(Standard Deviation), 
[Range] 
Mask Replicate 
1 2 3 
1 616.3 601.3 596.5 604.7 (42.7), [526-703] 
1R 580.9 576.3 620.6 592.6 (60), [466-696] 
2 669.5 497.3 - 583.4 (108.1), [434-739] 
1A 559.4 - - 559.4 (62.3), [430-642] 
1FD 15 - - 14.6 (51.3), [0-199]* 
1PD 391.5 - - 391.5 (68.3), [217-458]* 
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Table A.6. Raw Tidal Volume Data: Mask 1. Tidal volume data was collected for the 
new, unused Laerdal® bag-valve-mask. 
 
Tidal Volume (mL) 
Mask Replicate 
1 2 3 
657 526 599 
602 657 615 
565 608 635 
588 591 610 
595 612 600 
623 630 610 
638 539 541 
703 596 569 
650 640 527 
542 614 659 
 
 
Table A.7. Raw Tidal Volume Data: Mask 1R. Tidal volume data was collected for the 
reprocessed (n=20 cycles) Laerdal® bag-valve-mask. 
 
Tidal Volume (mL) 
Mask Replicate 
1 2 3 
579 644 509 
466 546 635 
470 560 547 
584 608 654 
640 548 673 
626 513 593 
547 589 672 
565 595 696 
640 578 636 
692 582 591 
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Table A.8. Raw Tidal Volume Data: Mask 2. Tidal volume data was collected for two 
replicates of a new, unused Ambu® SPUR® II bag-valve-mask. 
 
Tidal Volume (mL) 
Mask Replicate 
1 2 
716 464 
739 453 
713 443 
704 434 
679 457 
687 470 
651 550 
565 522 
586 513 
655 667 
 
 
Table A.9. Raw Tidal Volume Data: Destructed Masks. Tidal volume data was 
collected for one abraded mask, one fully deflated mask, and one partially deflated mask. 
 
Tidal Volume (mL) 
1A 1FD 1PD 
513 0 432 
430 20 389 
569 0 458 
585 0 419 
590 0 398 
593 0 378 
622 0 304 
517 199 404 
642 0 424 
533 0 217 
 
 
 
  
 93 
Appendix B 
 
Test Conditions and Protocols 
Figure B1. Staphylococcus epidermidis preparation. A 2% aseptic transfer of one 
ATCC 12228 Culti-Loop™ (Thermo Scientific™) into sterile tryptic soy broth was made 
and incubated for 24 hours at 37°C. 
 
 
Figure B2. Standard Plate Count Protocol. The standard plate count method was used 
to determine the number of colony-forming units (CFU) during microbiological testing. 
  
In biological safety cabinet, 
sterile scissors are used to 
aspetically transfer one S. 
epidermidis loop to bottle of 
98 mL sterile tryptic soy broth 
(1:49 dilution).
Lid is secured on 
bottle and contents 
gently agitated 
manually for 15 
seconds. Lid 
immediately 
loosened.
Tryptic soy 
broth + S. 
epidermidis 
loop incubated 
for 24 hours at 
37°C.
Plates are removed from 
incubator and inverted 
(if not inverted already) 
so that the bottom of the 
petri dish is facing up.
Count CFUs 
(individual white, 
round dots in the 
case of S. 
epidermidis) with 
permanent marker 
on every plate that 
exhibited growth. 
Countable range is 
30-300.
To determine the 
bacteria count 
(per mL) for the 
specimen, take 
the plate count 
average for that 
dilution and 
divide it by the 
dilution 
concentration.
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Figure B3. Ruhof ATP Complete® Protocol. ATP testing determined the presence of 
adenosine triphosphate and followed manufacturer’s instructions, which are detailed in 
the figure below. 
 
 
After removing test swab cap, one site 
(varying in size depending on study) is 
tested from each sample using the 
provided ATP test swab. Cap is placed 
on swab until handheld device is 
powered on and ready for measurement.
Snap valve is broken and 
squeezed twice to release 
liquid inside test swab. 
Test swab is gently shaken 
for 5 seconds and then 
inserted into the ATP 
handheld device. 
'OK' button is 
pressed on 
handheld 
device and an 
ATP reading 
is given in 15 
seconds.
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Figure B4. Bleach pH Change Over Time. Fresh 0.5% sodium hypochlorite solutions 
were prepared, and the pH was monitored over time as various amounts of organic matter 
were added. This was done to find stable pH decay after the addition of organic matter 
for the protocol efficacy study. After roughly 10 minutes after adding organic matter 
(Artificial Mucus Soil), pH decreased at a steady rate. 
 
 
 
 
y = -0.0059x + 11.313
R² = 0.9954
8
8.5
9
9.5
10
10.5
11
11.5
-3 2 7 12 17 22 27 32 37 42
p
H
Time (minutes)
Bleach pH Change (With and Without Added Organic Matter)
30 mL, 10 dips (1) 30 mL (2)
60 mL, 20 dips (1) 100 mL, 33 dips (1)
Bleach (no soil) (2) Linear (Bleach (no soil) (2))
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Table B1. Artificial Mucus Soil Recipe. Test soil recipe taken from the ASTM F3208 
standard. Mucin was added to water and stirred at approximately 380 rpm for 4-5 hours 
or longer. The remaining ingredients were added while the stir bar was in the mixture. 
After removal from stirrer, final volume of water was added. Finally, pH was adjusted 
using 0.1M HCl to 6.75. 
*Used 1.5 1-mL vials due to high material costs and resource constraints 
 
  
Component Amount (Original) Amount (for ~ 1L) 
Pig mucin 100 mg 1,1230 mg 
Casein hydrolysate 500 mg 5,650 mg 
Sodium chloride (NaCl) 500 mg 5,400 mg 
Diethylenetriaminepentaacetic 
acid (DPTA) 
0.59 mg 6.67 mg 
Water 80 mL 901.4 mL 
Potassium chloride (KCl) 500 mg 5,650 mg 
Salmon sperm DNA 140 mg* ~1.5 mL* 
Egg yolk emulsion 232 mg 5.14 mL 
Water (final addition) 20 mL 226 mL 
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Appendix C 
 
Human Factors Documents 
 
Table C.1. Task Analysis for Usability Study. 
Scores will be given as follows: 
0- participant fails to properly complete step 
1- participant completes step, but with some difficulty 
2- participant completes step with ease 
Participant 
1 2 3 
1. 
  Make 0.5% 
bleach 
solution 
1 
Put on 
appropriate PPE 
(gloves, safety glasses). 
Notes    
Score    
2 
Correctly measure out 
solutions for correct 
percentage (using 1/10 
dilution, or 1 part 
“bleach” + 9 parts 
water) and places in 
provided containers. 
Notes    
Score    
3 
Mix the measured 
solutions. 
Notes    
Score    
Section debrief notes:  
 98 
2. Prepare for 
decontaminat
ion 
1 
Ensure 
  appropriate PPE 
(gloves, safety 
glasses...may have 
already completed this 
in previous step). 
Notes    
Score    
2 
Read the instructions in 
entirety. 
Notes    
Score    
3 
Locate the necessary 
components (BVM, 
clock, bins). 
Notes    
Score    
Section debrief notes:  
3. Submerge 
BVM in 
bleach 
solution 
1 
Place BVM in correct 
bin. 
Notes    
Score    
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2 
Ensure the BVM is 
fully submerged in bin. 
Notes    
Score    
3 
Time the step to ensure 
it is submerged for 10 
minutes. 
Notes    
Score    
Section debrief notes:  
4. Prepare to 
wipe 
contaminated 
surfaces with 
cloth 
1 
Take off old gloves and 
dispose of them 
properly. 
Notes    
Score    
2 
Cover the 
decontamination 
container. 
Notes    
Score    
3 
Put on new gloves and 
ensure a cloth is 
soaking in a chlorine 
solution for future 
steps. 
Notes    
 100 
Score    
Section debrief notes:  
5. Wipe 
surfaces with 
cloth 
1 
Open the 
decontamination 
container, ensuring the 
BVM stays submerged 
if cloth was placed in 
bin. If not placed in the 
bin, make sure the cloth 
was soaked in chlorine 
solution. 
Notes    
Score    
2 
Fully wipe off the 
surfaces the BVM 
touched with the cloth. 
Notes    
Score    
3 Switch gloves properly. 
Notes    
Score    
Section debrief notes:  
6. Remove 
BVM from 
chlorine 
container 
1 
Ensure new gloves 
have been put on after 
previous step (may 
have already 
completed) 
Notes    
Score    
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2 
Remove BVM from the 
bleach solution 
container 
Notes    
Score    
3 
Move the BVM to the 
soapy solution, 
ensuring no spilling 
while 
removing/transport. 
Notes    
Score    
Section debrief notes:  
8. Place 
BVM 
  in soapy 
water 
solution 
1 
Prepare soap solution 
(use dilution of 1/11, or 
1 part soap to 10 parts 
water) in provided 
container. 
Notes    
Score    
2 
Place BVM in soapy 
container for 10 
minutes. 
Notes    
Score    
Section debrief notes:  
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9. Finish 
disinfection 
process for 
BVM 
1 
Remove BVM unit 
from soapy water and 
transfer to clean water 
container. 
Notes    
Score    
2 
Dry the device (not 
specified in protocol--
drying with lint-free 
clean cloth soaked in 
alcohol is best, 
followed by air dry). 
No need to “send to 
sterilization” for this 
device. 
Notes    
Score    
Section debrief notes:  
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Figure C.1. Bleach-Based Reprocessing Protocol. The following protocol is used in the 
urban Tanzanian hospitals for the general decontamination of devices without electrical 
components. 
 
Preamble: Decontamination is the process that makes inanimate objects safer to handle 
by staff before cleaning (i.e. inactivates Hepatitis B Virus, Hepatitis C Virus, and Human 
Immunodeficiency Virus, and reduces the number of microorganisms but does not 
eliminate them) 
Policy Statement: All medical staff must decontaminate soiled instruments before 
cleaning. 
Decontamination solutions used: 0.5 % chlorine, liquid soap, tap water 
Procedure: 
1. Decontamination is the first step in handling used instruments and other items that 
have been in contact with blood or body fluids. 
2. Leave surgical or examination gloves on post procedure or put on utility gloves. 
3. Place all instruments in 0.5% chlorine solution for 10 minutes for 
decontamination. Immediately after completing the procedure, make sure that all 
devices are submerged in the solution. 
4. Remove surgical gloves by turning inside out and dispose of gloves in a leak-
proof waste container or heavy-duty plastic bag. 
5. Cover the decontamination container. 
6. Using utility gloves, clean all surfaces contaminated during procedure by wiping 
them with a cloth soaked in 0.5% chlorine solution. 
7. Remove instruments from 0.5% solution after 10 minutes and immediately take 
them for cleaning. 
8. Place the instruments in the container with soapy water that has been diluted 1:10 
for 10 minutes. 
9. Then remove the instruments and dip in the container with clean water rinse, then 
dry and send for sterilization. 
Guidelines:  
● Change the decontamination solution daily, or more often if necessary (change 
when it becomes dirty).  
● Use plastic non-corrosive containers for decontamination to prevent dulling of 
sharps (e.g. scissors).  
● Do not soak instruments that are not 1.10% stainless steel even in plain water. 
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Table C.2. Protocol Step Timing. 
Step Time Duration of Step 
1 
Start time:  
 
Participant finishes reading 
protocol 
 
2 
Participant places BVM in bleach 
bin 
 
 
Participant removes BVM from 
bleach bin 
 
3 
Participant wipes surrounding 
surfaces with bleach-soaked cloth 
  
4 
Participant places BVM in soapy 
water bin 
 
 
Participant removes BVM from 
soapy water bin 
 
5 
Participant places BVM in 
deionized water bin 
 
 
Participant removes BVM from 
deionized water bin and places 
out to dry 
 
6 End Time:   
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Figure C.2. Follow-Up Interview Questions. 
Please rate the following statements on a scale of 1 to 5, 1 being strongly disagree and 5 
being strongly agree. Example:  
           1     2        3         4           5 
          ◯          ◯          ◯        ◯       ◯ 
Strongly disagree     Disagree            N/A     Agree        Strongly agree 
1. This decontamination process was straightforward and easy to understand. 
          ◯          ◯          ◯        ◯       ◯ 
Strongly disagree     Disagree            N/A     Agree        Strongly agree 
(If participant chooses value of 2 or less OR 4 or more, ask them why) 
2. I was confident in my ability to follow the protocol. 
          ◯          ◯          ◯        ◯       ◯ 
Strongly disagree     Disagree            N/A     Agree        Strongly agree 
(If participant chooses value of 2 or less OR 4 or more, ask them why) 
3. I was able to clean the device thoroughly. 
          ◯          ◯          ◯        ◯       ◯ 
Strongly disagree     Disagree            N/A     Agree        Strongly agree 
(If participant chooses value of 2 or less OR 4 or more, ask them why) 
4. Is there anything you would change about this protocol to improve your 
experience? 
 
 
5. To what extent have you had experience cleaning something like this (i.e. in a job 
at a restaurant/babysitting, wet lab experience in college courses, handling of liquid 
chemicals, etc.)? If so, explain. 
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Table C.3. Researcher Response Guide. Due to the nature of the study, the research 
team can only answer certain questions. These questions and appropriate responses are 
listed in this table. 
Question from 
Participant 
Question Intent Response 
Where is [insert 
item]? 
Seeking Clarity (location of 
an item if they can’t find it) 
[Show participant where an item is 
if they cannot find it] 
Does this look 
right? 
Verifying Correct 
Execution of Step 
We cannot provide any 
information on that. [Encourage 
participant to continue in 
completing step & moving 
forward] 
Can I use my 
phone to keep 
time? OR Do you 
have something I 
can use to keep 
time? 
Verifying Acceptable 
Action 
(A clock will be visible in the 
room and a timer is available upon 
request) Yes! 
How do I take this 
apart? OR Do I 
have to take this 
apart? 
Seeking Clarity (Not in 
protocol) 
We cannot provide any 
information on that. [Encourage 
participant to continue in 
completing step & moving 
forward] 
Will the bleach 
solution damage 
my clothes or 
skin? 
Seeking Clarity (safety) 
This solution is not bleach.  It is 
similar but should not damage 
your clothes or yourself. 
How long does 
the cloth need to 
soak? 
Seeking Clarity (Not in 
protocol) 
We cannot provide any 
information on that. [Encourage 
participant to continue in 
completing step & moving 
forward] 
How do I make 
the soapy solution 
OR how much 
water and soap 
am I supposed to 
Seeking Clarity (not a 
specific amount in 
protocol) 
We cannot provide any 
information on that. [Encourage 
participant to continue in 
completing step & moving 
forward] 
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use? 
Am I supposed to 
wait exactly 10 
minutes for each 
step? 
Seeking Clarity (confusion 
over extent of study) 
We cannot provide any 
information on that. [Encourage 
participant to continue in 
completing step & moving 
forward] 
Why are you 
recording my 
hands but not my 
face? 
Seeking Clarity (Protocol) 
We would like the opportunity to 
revisit your study, but we do not 
want to collect your personal 
information, including your face. 
Is this done? OR 
What is next? 
Verifying Completion 
We cannot tell you any 
information on that.  If you believe 
you are done, please tell us that 
you are finished. 
What is a Bag 
Valve Mask 
(BVM)? 
Seeking Clarity (unknown 
device to them) 
A Bag Valve Mask is used to help 
patients breathe when they are not 
or having major complications. 
 
 
